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Abstract 
 
Prostate cancer affects many older men and is the most commonly diagnosed 
cancer in Australia after non-melanoma skin cancers. The need for better testing 
methods for diagnosis and follow-up is necessary as the current pathology based 
test is sensitive but not specific for just prostate cancer. It can also be elevated in 
the normal prostate and in benign prostatic conditions. Studies have shown that the 
use of circulating exosomes may be useful in detecting cancers, particularly the 
exosomes in seminal fluid as they are prostate specific. Multiple studies have shown 
that exosomes themselves can be manipulated into packaging and transporting 
chemotherapeutic agents and particular enzymes to specific areas of the body. 
Exosomes pre-packaged with chemotherapeutic drugs may lead to a more specific 
treatment method. An important group of enzymes in cancer biology are the 
glutathione transferases. Their presence in prostate cancer has been studied, 
however the main focus has been on the methylation of GSTP1 and the 
polymorphisms of GSTT1, GSTM1 and GSTM3 in several populations. Due to the 
lack of functional studies regarding these enzymes, the effect that they have on 
prostate cancer was examined. Prostate cancer cell lines ranging from androgen 
sensitive to androgen resistant were used to first determine the GST profile. RT-
PCR and Western blot analysis was used to make expression and protein profiles of 
each GST enzyme. According to the GST profile, over-expressing GSTM1 in 22Rv1 
cells (androgen dependent) was an appropriate choice as GSTM1 was not present 
in either 22Rv1 lysates or exosome preparations. These engineered cells and the 
exosomes they shed were then used in functional studies looking at cell 
proliferation. It was observed that the proliferation of GSTM1 over-expressing cells 
decreased however when in the presence of docetaxel, proliferation actually 
increased. Chemotherapy studies using docetaxel were performed as it is a 
common drug used for treating castrate resistant prostate cancer. Exosomes shed 
from the 22Rv1-M1 cells were shown to protect cells from docetaxel and increase 
prostate cancer cell growth. The data from this study showed functional links 
between GSTM1, exosomes and the progression of prostate cancer. 
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Chapter 1: Literature Review 
 
1.1 INTRODUCTION 
Prostate cancer (PCa) is the most commonly diagnosed cancer in Australian 
men, excluding non-melanoma skin cancers. According to the most recent data from 
the Australian Institute of Health and Welfare there were 19,993 new cases of 
prostate cancer diagnosed in 2011. This number is expected to increase to around 
25,000 new cases per year by 2020 due to an increase in the number of men 
presenting for testing, improvements to diagnostic testing and the aging population 
in Australia. Whilst the mortality rates are decreasing and are expected to continue 
decreasing by 2020, in 2012, 3,070 men died from prostate cancer [AIHW, 2012].  
There are many risk factors associated with the increased chance of developing 
PCa. The risk of developing PCa increases with age as men under the age of 50 are 
unlikely to be diagnosed with PCa however in those aged 85 and over, there is a 
20% chance of diagnosis. Family history increases the risk of PCa as men with a 
parent, sibling or child with PCa are twice as likely to develop PCa compared to 
other men. Ethnicity is also an important risk factor as African Americans are more 
likely to develop PCa than Asians. Lifestyle factors such as a high fat or high 
calcium diet and environmental factors such as smoking and exposure to 
carcinogenic compounds are also related to an increased risk of PCa [AIHW, 2013]. 
The progression of PCa involves a multistage process where a small carcinoma of 
low histological grade can slowly progress towards metastatic lesions of higher 
grade [Gingrich, 1997]. Often, PCa is an adenocarcinoma with well-defined 
glandular patterns. It also has a clinically useful biomarker which is used for 
diagnosis and during treatment – prostate-specific antigen (PSA) [Byar, 1972, 
Stamey, 1987]. The PSA test is sensitive but is unable to differentiate between 
benign prostatic conditions such as benign prostatic hyperplasia, indolent PCa and 
aggressive PCa [Duijvesz, 2010].A considerable scientific focus is now on the 
identification of biomarkers that can identify the presence of aggressive PCa that will 
cause the death of a patient and should be aggressively treated, and indolent PCa 
that does not require treatment and will not be terminal in the patients normal life. 
Exosomes have been shown to be released from a variety of cells, especially 
cancer cells and are present in all bodily fluids. Their function is yet to be fully 
understood however cancer cell released exosomes appear to be involved in cancer 
progression, communication and formation of the metastatic niche [Jung, 2009].  
Identification of prostate cancer specific exosomes in the blood, semen and urine of 
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patients with prostate cancer, and in particular, prostate cancer specific proteins, 
lipids, DNA sequences and RNA sequences carried by these exosomes, might 
provide a new and relatively non-invasive option for identifying aggressive PCa.  
The focus of this study was the family of detoxifying enzymes called Glutathione 
S-transferases. Several members of this family have been shown to be involved in 
cancer progression and in prostate cancer the cytosolic GST enzymes GSTP1, 
GSTT1 and GSTM1 are particularly relevant. As cytosolic proteins are often 
included as cargo in exosomes, it was hypothesised that GST enzymes over-
expressed by prostate cancer cells are loaded into exosomes and can influence the 
growth of cells in the tumour microenvironment, and may contribute to the 
development of resistance to chemotherapies like docetaxel. 
 
1.2 AIMS AND SIGNIFICANCE OF THE STUDY 
Exosomes have been shown to be involved in the progression of local PCa and 
distant metastases and this is believed to be via cargo macromolecules contained 
within. PCa cells that release exosomes may contain GST enzymes as cargo which 
may contribute to the progression of the disease and could be useful biomarkers for 
diagnosis and prognosis and/or potential therapeutic targets. 
 
This project had 3 specific research aims. 
1. To profile GST expression in prostate cancer cell lines and determine whether 
expressed GST enzymes appear as cargo in exosomes released from these 
cells. 
2. To determine whether over-expression of a GST enzyme in a GST naïve cell line 
results in the loading of the GST into exosomes from that cell line and whether 
these GST-positive exosomes alter the in vitro growth behaviour of PCa cells and 
associated stromal cells.  
3. To determine if GST over-expression increases resistance to docetaxel and if 
exosome delivery of GST enzymes to a GST negative line could also confer 
docetaxel resistance.  
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1.3 REVIEW OF THE LITERATURE 
1.3.1 CHARACTERISTICS OF THE PROSTATE AND PROSTATE CANCER 
The incidence of PCa increases in men with particular risk factors which can 
be characterised as either non-modifiable factors or modifiable factors. Age is the 
most important non-modifiable factor as the incidence of PCa increases rapidly with 
age, especially in the seventh decade of life. The relative risk of developing PCa is 
also higher in men who have a first-degree relative with PCa than in men without a 
first-degree relative with PCa. This risk is also higher in men younger than 65 years 
with a first-degree relative than in older men with a first-degree relative with PCa, 
especially if the affected relative is a brother and not a father [Kiciński, 2011]. 
Modifiable risks include smoking, diet, weight and physical activity and all of these 
risks are associated with a moderate increase in PCa risk. Increased body-mass 
index is also associated with an increase in advanced PCa [Huncharek, 2010; 
Discacciati, 2014]. 
The definitive diagnosis of PCa depends on the presence of an 
adenocarcinoma on prostate biopsy cores or operative specimens. Transrectal 
ultrasonography (TRUS) guided biopsy of the prostate is the most widely accepted 
method to collect histological specimens to diagnose PCa. Currently, the main 
indications for prostate biopsy include an abnormal digital rectal examination (DRE) 
or elevated serum PSA level. This however is problematic as many patients 
undergoing prostate biopsies often show negative histology results that result in 
false negative results and requires a repeat biopsy to confirm the adenocarcinoma. 
It is evident that refinements in patient selection for biopsy are required. Advances in 
molecular biology and radiologic imaging are generating novel data allowing 
clinicians to identify patients needing a prostate biopsy with a greater degree of 
accuracy [Pal, 2012]. 
In practice, serum PSA is highly prostate specific however it is not prostate 
cancer specific. Non-malignant prostatic conditions can also result in elevated 
serum PSA which reduces the PCa specificity of measuring the serum levels 
[Thompson, 2004]. Furthermore, the inability of PSA testing to separate indolent 
from high grade aggressive disease leads to major drawbacks in the clinical setting, 
however routine PSA screening is still one of the best clinical tests available for 
PCa. It reduces disease-specific mortality by detecting early prostate tumours that 
are still responsive to radical treatment with curative intent [Zappa, 2014]. Advocates 
of screening argue that the acceptable and inexpensive PSA test may reduce the 
significant mortality caused by PCa through earlier detection and treatment of organ-
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confined disease. As a result of the low specificity of PSA and the high number of 
clinically latent PCa, those against screening argue that there would be unnecessary 
biopsies, diagnosis and treatment and that healthcare systems would suffer from 
spending money on unnecessary curative treatments and side effects. Despite 
these drawbacks, many studies have shown that early testing of serum PSA may 
determine the risk of future PCa. The odds ratio of being diagnosed with PCa was 
shown to be 19 times higher in men with a PSA of 2.0-3.0 ng/mL at 50 years of age 
in comparison of those individuals with a PSA of <0.5 ng/mL with the median time 
from PSA testing to cancer diagnosis of 17 years [Lilja, 2007]. Those with higher 
PSA values at an early age were more likely to be diagnosed with advanced cancer 
[Ulmert, 2008]. Recent data confirming these findings showed that patients with PSA 
>2.0 ng/mL at the age of 60 years are at an increased risk of dying from PCa than 
those with PSA below this threshold who had an almost negligible risk of clinically 
significant cancer [Vickers, 2010]. Although the overall risk of mortality remains low, 
over 90% of PCa deaths occur in patients with PSA >2.0 ng/mL at the age of 60 
[Vickers, 2010]. This data suggests that an early PSA reading in men may 
determine the intensity of future PCa screening.  
 
1.3.2 CURRENT TREATMENT OF LOCALISED AND METASTASISED 
PROSTATE CANCER 
 PCa treatment is dependent on the life expectancy and co-morbidities of the 
patient but more importantly, on patient preference for the type of procedure that 
may be involved, potential long term side effects and overall quality of life. Risk 
assessment depends on the grade and stage of the tumour as well as the PSA 
result. The tumour is graded according to the Gleason grading system on tissue 
from a core-needle biopsy. The tissue is given two grades between 1 and 5; 1 
indicating well-differentiated tissue and 5 indicating poorly-differentiated tissue. The 
two grades are then added together and this is known as the Gleason score 
[Gleason, 1974].T staging of localised and locally advanced PCa is based on 
specific criteria: T1 refers to an impalpable tumour,T2 is where the tumour is 
confined to one or both lobes, T3a is where the tumour is on the outside capsule 
and T3b tumours have progressed into the seminal vesicle. In Australia, risk 
grouping is used where low risk PCa is T1 or T2 with a Gleason score of ≤ 6 and 
PSA of ≤ 10.0 ng/mL. High risk patients have a T3 tumour, and Gleason score of 8-
10 or PSA of > 20.0 ng/mL (Figure 1.1). Patients that are classified as an 
intermediate risk are those whose T score, Gleason score and PSA result falls 
between the high and low risk values as described above [Duchesne, 2011]. 
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Figure 1.1: The T staging of localised and locally advanced prostate cancer. 
T3a* and T3b* lesions are extraprostatic and are generally managed with radiation therapy 
and androgen deprivation therapy. Adapted from: Duchesne, 2011. 
 PCa treatments are aimed to eradicate the cancer whilst minimising 
treatment-associated side effects and costs. The goal for treating localised PCa is to 
target patients who are likely to benefit from intervention and minimise treatment-
related complications as well as avoiding disability or death. Treatment depends 
upon patient-related factors such as any existing comorbidities, age, life expectancy 
and treatment preferences and also depends on treatment-related factors like the 
efficacy of the treatment, adverse effects and any potential treatment complications 
[Nelson, 2013; Zeliadt, 2006]. There are many different treatment options available 
for patients with early-stage PCa including radiation therapy, brachytherapy, 
cryotherapy and radical prostatectomy. These therapies can be combined; 
brachytherapy with radiation therapy are often considered, however the risks and 
side effects vary for each treatment [Marberger, 2012]. Radiation therapy includes 
multiple doses of radiation from an external source applied over several days to 
weeks to eradicate PCa cells [AHRQ, 2008]. In locally advanced as well as high-risk 
patients, radiation may be combined with hormonal therapy which may improve 
efficacy [NIH, 2014]. Brachytherapy includes using radioactive implants placed 
under radiologic guidance to emit radiation to cancer cells. Permanent (low dose 
rate) or temporary (high dose rate) brachytherapy may be used. Cryotherapy 
involves the destruction of cells by rapid freezing and thawing using transrectal 
guided probe placement and injection of freezing/thawing cryo gases. Radical 
prostatectomy is the surgical removal of the entire prostate gland with seminal 
vesicles, ampulla of vas and sometimes, the pelvic lymph nodes. It includes 
conventional techniques like open retropubic or open perineal, and newer 
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techniques such as laparoscopic and robotic-assisted approaches [AHRQ, 2008]. 
The advantages of newer laparoscopic and robotic-assisted approaches include 
reduced blood loss, faster convalescence and shorter hospital stays [Allen, 2012]. 
 Another important aspect of prostate cancer is the androgen receptor (AR). 
The normal development and maintenance of the prostate is dependent on 
androgen acting through the AR and expression is maintained throughout prostate 
cancer progression. Mutations of the AR may contribute to the progression of 
prostate cancer and the failure of endocrine therapy by allowing AR transcriptional 
activation in response to anti-androgens. By inhibiting AR activity, this may delay 
prostate cancer progression [Heinlein, 2004]. Hormone therapies include androgen 
deprivation therapy (ADT) where injectable medications are used to lower 
testosterone levels, or the surgical removal of testicles to lower or block circulating 
androgens [AHRQ, 2008]. ADT is one of the most common forms of treatment for 
advanced PCa. The aim of ADT is to lower the levels of testosterone and other 
androgens to castrate levels, based on the fact that testosterone is a key driver of 
PCa. Combination therapies with ADT and radiotherapy have shown to improve 
cancer control and overall survival in early-stage PCa for intermediate- and high-risk 
patients as well as in men with locally advanced PCa [Horwich, 2013; Resnick, 
2012]. ADT can normalise serum PSA in over 90% of patients and results in a 
sizeable tumour response in 80 to 90% of cases. This treatment occurs with either 
bilateral orchiectomy (surgical castration) or medical castration (using a luteinizing 
hormone releasing hormone (LHRH) agonist or antagonist). The most widely used 
approach is continuous treatment with LHRH agonists in conjunction with an AR 
antagonist [Resnick, 2012]. ADT can however lead to various adverse effects 
including decreased libido, impotence, hot flashes, osteopenia with increased 
fracture risk, metabolic alterations and changes in mood and cognition [Widmark, 
2009]. Metabolic complications include obesity, insulin resistance and dyslipidaemia 
and the long-term use of ADT has also shown deleterious effects on cardiovascular 
health [Ahmadi, 2013]. ADT is initially successful however many men become 
resistant to ADT and will relapse. This stage is known as castrate resistant prostate 
cancer (CRPC). 
 CRPC is treated by inhibiting the androgen-receptor axis. This can be 
achieved by a maximum reduction of androgen activity. The basic treatment strategy 
includes complete inhibition of testosterone production in the testicles as a result of 
using LHRH agonists. Simultaneously, new medications are introduced showing a 
cytotoxic effect, such as docetaxel or cabazitaxel, or other drugs that block the 
prostatic production of testosterone (abiraterone) which may lead to a further 
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reduction of testosterone concentration or block the androgen receptor 
(bicalutamide). The use of docetaxel, made from the needles of the Pacific Yew 
tree, was FDA approved in 2004 for the treatment of metastatic androgen-
independent prostate cancer and has shown to be very effective in CRPC 
[Eisenberger, 2012]. Despite using these particular medications, the main source of 
testosterone production, the hypothalamic-pituitary-gonadal axis, remains active. 
Regardless of the failure of first-line hormone therapy, LHRH is crucial for effective 
treatment. Retrospective studies evaluating the effects of continued hormone 
therapy in patients with CRPC have shown longer overall survival in patients using 
LHRH agonists, regardless of hormone resistance [Recine, 2015; Silberstein, 2013]. 
A summary of the commonly employed treatment strategies is summaries below in 
Figure 1.2. 
 
 
Figure 1.2: The progression of prostate cancer and the common therapies 
used at each stage. The treatment of prostate cancer is highly stage dependent as 
different therapies are used at the initial diagnosis, such as localised surgery and radiation, 
and then in CRPC where a combination of chemotherapeutic drugs is often employed. 
Adapted from: http://scotdir.com/health-and-fitness-2/prostate-cancer-treatment. 
 
1.3.3 THE PRODUCTION OF EXOSOMES AND HOW TO CHARACTERISE THEM 
Exosomes are small lipid vesicles secreted from cells that contain bioactive 
molecules. Within cells, the fusion of multivesicular bodies (MVBs) with the plasma 
membrane causes the release of intraluminal vesicles (ILVs) into the extracellular 
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environment. These vesicles are known as microvesicles, or exosomes [Raposo, 
1996]. The sorting of extracellular vesicle (EV) cargo during the internal budding of 
the membrane that leads to ILV formation is an essential step in exosome 
biogenesis. The endosomal-sorting complex required for transport (ESCRT) is 
responsible for the accumulation and sorting of molecules that are channelled into 
the ILVs (Figure 1.2) [Morvan, 2012; Adell, 2014]. The ESCRT contains four main 
complexes (ESCRT-0, -I, -II and -III) which are responsible for the final delivery of 
ubiquitinated proteins to the degradation machinery. It has been shown that the 
depletion of specific ESCRT-family members is able to alter the exosome protein 
content and the rate of exosome release from cancer cells [Colombo, 2014]. 
PDCD6IP (Alix) and tumour susceptibility gene 101 (TSG101) are involved in the 
formation of ILVs that are then released as exosomes [Kowal, 2014]. Alix was 
recently reported to interact with syndecans by the cytosolic adaptor syntenin which 
leads to exosome formation in MCF-7 and HeLa cells [Baietti, 2012]. Proteins 
frequently found to be involved in exosome biogenesis in other systems, such as 
TSG101, have been used as exosome markers in benign and cancer models 
however reports demonstrating their functional role in the formation of exosomes are 
lacking.  
Exosomes are membrane-bound, 30-120 nm in diameter and contain proteins, 
lipids, nucleic acids - DNA, mRNA and microRNAs. Exosomes have been isolated 
and purified in various biological fluids such as seminal fluid, urine, blood, breast 
milk and from the conditioned media of in vitro cultures of numerous cell types. They 
have also been considered to be a potential source of biomarkers for several 
diseases due to their ubiquitous presence and stability in biological fluids. Several 
studies have also indicated that exosomes play a role in immune responses and are 
involved in the pathogenesis of various diseases such as Parkinson’s disease, 
Alzheimer’s disease, breast cancer, melanoma, pancreatic cancer and in many 
other cancer types [Phuyal, 2014]. 
Some tumour cells spontaneously release large plasma membrane-derived 
extracellular vesicles (PM-derived EVs) containing metalloproteinases with pro-
invasive properties [Di Vizio, 2012; Muralidharan-Chari, 2009]. The release of PM-
derived EVs is more commonly induced by stimuli leading to a rise in intracellular 
calcium and cytoskeleton remodelling [Pasquet, 1996]. Calcium ionophores directly 
trigger MV release as well as extracellular signals like formyl-Met-Leu-Phe on 
neutrophils and simple feeding of tumour cells with media containing fresh FCS 
[Hess, 1999; Ginestra, 1997]. Unexpected triggers also stimulate or modify exosome 
9 
 
secretion. In some studies, to avoid co-culture with FCS-derived exosomes with cell-
derived exosomes, cells are changed to FCS-free medium and the stress caused by 
this abrupt starvation results in altered quantitative and/or qualitative exosome 
secretion [Li, 2015]. The common differences between extracellular vesicles is 
outlined in Table 1.1 
 
Figure 1.2: The biogenesis of exosomes. The plasma membrane buds inwards 
forming a membrane-bound vacuole. Exosomes are formed from MVBs, also known as late 
endosomes, originally derived from lysosomes. The production of exosomes can be 
triggered by many factors including extracellular stimuli like microbial attack and other 
stresses. Exosomes can be released into the extracellular environment by fusion of MVBs 
with the cell surface [Kourembanas, 2015]. 
Exosomes have successfully been purified from conditioned medium of in vitro 
cell cultures. The original and most commonly used protocol for exosome 
purification involves several centrifugation and ultracentrifugation steps. In some 
cases, the first centrifugation steps can be replaced by a single filtration step. An 
extra purification step involving sucrose gradients yields very pure exosomes. 
Exosomes are also able to be trapped on beads that are covered by an antibody 
specific for exosomal surface proteins [Théry, 2006; Clayton, 2001]. The 
identification of vesicles as exosomes requires morphological analysis due to their 
small size by visualisation with an electron microscope (EM). The purity of exosome 
preparations as well as their characterisation should be determined by EM.  
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Table 1.1: Main differences between extracellular vesicles, in vitro 
isolation techniques, markers and size. 
Microvesicles Size Origin Features 
Exosomes 30 - 120 nm 
diameter 
Endosome Simple phospholipid 
bilayer 
Markers - TSG101, 
CD9, Alix, CD63, 
Hsp70 
Prostasomes 50 - 500 nm 
diameter 
Unclear - membranes that 
are rich in cholesterol and 
sphingolipids including the 
plasma membrane, late 
secretory pathway, and 
endocytic compartments 
Cholesterol- and 
sphingomyelin-rich 
lipid multilayer 
PM-derived 
extracellular 
vesicles 
 Plasma membrane Contain 
metalloproteins 
Oncosomes 1 - 10 µm 
diameter 
Plasma membrane Non-apoptotic blebs 
Apoptotic 
bodies 
1 - 5 µm 
diameter 
Plasma membrane Annexin V positive 
Table 1.1 shows the different microvesicles that can be isolated in vitro, their origin and 
features used to identify these vesicles [Borges, 2013]. 
 
1.3.4 THE INVOLVEMENT OF EXOSOMES IN CELL-CELL COMMUNICATION 
 Examining the interaction of single exosomes with target cells is difficult as the 
resolution limit of optical microscopy is 200 nm and exosomes are smaller in size. 
Various studies however have analysed the bulk interaction of exosomes with 
recipient cells using fluorescence microscopy, flow cytometry or functional transfer 
of surface molecules. Exosomes have been shown to serve as “communication 
shuttles” between cells and can also transduce signals between cells. This 
communication may be responsible for re-encoding genes of target cells and is 
reported to play a part in the development of tumours, invasion and metastasis and 
creation of the metastatic niche [Azmi, 2013]. Exosomes contain the same adhesion 
molecules of their cell of origin andcan be captured through specific receptor-ligand 
interaction by target cells that specifically recognise them rather than just by any cell 
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that is present in the microenvironment. After this interaction, the recipient cells may 
behave differently [Lösche, 2004]. 
 Cells communicate in an auto-, para- and endocrine manner by sensing 
circulating endogenous bioactive compounds including proteins, lipoproteins, lipids 
and steroids, simpler compounds such as eicosanoids, monoamines, endorphins or 
cannabinoids and finally, extracellular miRNA molecules associated with protein 
chaperones. The majority of these signalling compounds are also found in 
exosomes. Microvesicles that target cells are able to produce varied biological 
effects resulting from direct exosome-cell stimulation and the action of transferred 
exosomal content. Exosomes release their content into an acceptor cell cytoplasm 
after clathrin-mediated endocytosis, phagocytosis or micropinocytosis [Ratajczak, 
2006]. 
 Once exosomes are shed, they can cover some distance which enables 
horizontal transfer of bioactive molecules and deposition of packaged bioactive 
effectors at distal sites [Muralidharan-Chari, 2010]. The cargo contained within 
exosomes is able to be released into a recipient cell but also into the extracellular 
environment which can result in consequences for the surrounding environment. For 
example, neutrophil-derived exosomes are packed with cytokines that release anti-
inflammatory molecules and then later, can function as pro-inflammatory mediators 
[Koppler, 2006; Mack, 2000]. 
 
1.3.5 EXOSOME PROFILING 
 Exosomal content has been well-studied and includes RNA and protein 
profiles. Interestingly, in some cases the RNA and protein content from exosomes 
have a different profile from that of their cell of origin even though they contain the 
same adhesion molecules marking their origin [Kogure, 2011; Lösche, 2004].  This 
would suggest that there is selective packaging of various proteins and nucleic acid 
sequences into the shed exosomes by the cell and these may be important to the 
functional purpose for exosome shedding. 
 Exosomes are distinguished from other shed released vesicles based on their 
cellular contents. For example, unlike apoptotic bodies, shed vesicles don’t contain 
cytosolic organelles or nuclear fragments [Taylor, 2008]. Furthermore, microvesicles 
are actin positive whereas cytoskeletal blebs are only transiently associated with the 
actin cytoskeleton during retraction [Charras, 2005; Paluch, 2005]. Proteins that are 
derived from the nucleus, mitochondria or endoplasmic reticulum are also excluded 
from the exosomal pathway [Schneider, 2013]. Figure 1.3 shows the content of 
exosomes that may not be present in all exosomes. 
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 In a recent study comparing the molecular profiling of docetaxel sensitive 
(Tax-sen) or docetaxel resistant (Tax-res) PCa derived exosomes (DU145 prostate 
cancer cell line), it was found that the resistant cells secreted a higher number of 
vesicles compared to the sensitive cells [Kharaziha, 2015]. In the same study, using 
clinical samples, the median number of particles present in the serum of CRPC Tax-
res patients was higher than in CRPC Tax-sen patients. It was also found that the 
exosomes secreted by the Tax-sen and Tax-res cells were not only different in 
number but also in the physical characteristics of the secreted exosomes. For 
example, the Tax-sen exosomes floated at a sucrose density of 1.12 to 1.19 g/mL 
whereas the Tax-res exosomes were present in a more narrow, although over-
lapping, sucrose density of 1.13 to 1.18 g/mL. Cellular component and protein class 
analysis further showed that the exosomes derived from these two cell lines have 
subtle yet distinct differences which may regulate their biological function on 
recipient cells. The Tax-res patients had a higher protein concentration of 
extracellular vesicles compared to the Tax-sen patients which suggests that these 
may be a source of protein biomarkers that can predict chemoresistance [Kharaziha, 
2015]. More recently, studies have reported that exosomes are involved in 
chemotherapy resistance [Challagundla, 2015; Bryniarski, 2015]. 
 Small nucleic acid sequences including miRNA are also found packaged 
within exosomes with the mechanism of exosome-mediated transfer of miRNAs first 
verified in 2007 [Valadi, 2007]. Exosomes have the ability to envelop specific 
miRNAs, protect the cargo whilst in circulation and function as a tool for invasive 
access while reflecting the condition of donor cells [Palma, 2012; Ge, 2014;Kowal, 
2014]. Exosomal miRNA is also a potential cancer biomarker. Interestingly, 
exosomes can be transfected with free extracellular miRNA which can then be used 
to target cells [Challagundla, 2015; Bryniarski, 2015]. 
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Figure 1.4: Overall composition of exosomes. Schematic showing exosome 
composition. Each listed component may be present in some exosomes and not others. 
Abbreviations: ARF, ADP ribosylation factor; ESCRT, endosomal sorting complex required 
for transport; LAMP, lysosome-associated membrane protein; MHC, major histocompatibility 
complex; MFGE8, milk fat globule-epidermal growth factor-factor VIII; RAB, Ras-related 
proteins in brain; TfR, transferrin receptor [Colombo, 2014]. 
1.3.6 THE INVOLVEMENT OF EXOSOMES INTUMOUR PROGRESSION 
 Tumour progression, metastasis and chemoresistance depend on the 
communication between the tumour itself and its surrounding microenvironment. 
Tumour cells can release exosomes in large quantities and if the number of 
circulating exosomes increases in patients with cancer this correlates with poor 
prognosis [Martínez, 2005]. It has been shown that the production of a metastatic 
niche is probably enhanced by the release of exosomes from the primary tumour 
cells as seen in Figure 1.4.  A few studies have also shown that exosomes shed by 
cancer cells can be taken up by stromal fibroblasts and other associated stromal 
cells suggesting communication between cancer and stromal cells that may also 
play a role in tumour cell spread. Rat pancreatic adenocarcinoma-derived exosomes 
may help form the pre-metastatic niche leading to the development of lung 
14 
 
metastasis [Jung, 2009]. Pre-metastatic changes in vivo were shown to be the result 
of the co-operation of exosomes and the soluble matrix. Exosomes may also 
transfer receptors between normal cells and tumour cells. Janowska-Wieczorek, 
[2001] showed the adhesion molecule CD41 can be transferred from platelets to 
tumour cells by exosomes, and provides the tumour cells with pro-adhesive 
properties. 
Invadopodia have emerged as a docking site for exosomes promoting cancer 
invasion [Hoshino, 2013]. Exosome secretion and invadopodia formation appear to 
be co-dependent as the inhibition of exosome biogenesis affects invadopodia 
formation and stability and in contrast, the inhibition of invadopodia formation greatly 
decreases exosome secretion. 
Exosomes influence the major type of stromal cells – cancer-associated 
fibroblasts, vascular endothelial cells and immune cells. Fibroblasts become 
“activated” as they progress through changes during the neoplastic process 
including morphologic and protein expression changes. Disorganised and 
uncontrolled growth as well as increased collagen production and hyaluronate 
synthesis stimulation also occur [Tlsty, 2001]. These activated fibroblasts are able to 
both hinder and promote tumour growth and progression, however this depends on 
the molecular state of the tumour epithelial cells. They are also capable of 
accelerating growth and promoting tumour cell invasion [Orimo, 2005; Camps, 1990; 
Gleave, 1991; Kaneruka, 2002; Sameshima, 2000]. Cancer exosomes can trigger 
fibroblast transformation through the TGF-β/Smad pathway and stimulate effects 
unique from soluble TGF-β [Gu, 2012; Webber, 2010; Webber, 2015]. When tumour 
fibroblasts were co-cultured with non-transformed epithelial cells, immature 
pleomorphic epithelial cells with enlarged nuclei and aberrant mitosis could be seen. 
These cells had an increased rate of proliferation, lost their polarity and changed cell 
cycle protein expression. p53, PCNA, Ki67 and cytokeratin expression were 
increased and in contrast, p21 nuclear expression and Bcl2 were decreased [Atula, 
1997]. 
For a tumour to grow beyond a few cubic millimetres, the tumour cells require 
access to the host vasculature andthe ability to divert blood to the tumour. The 
creation of a tumour blood supply requires a significant increase of pro-angiogenic 
factors to overcome the anti-angiogenic factors [Bergers, 2003]. Exosomes have 
been shown to play a role in increasing angiogenesis. Once hypoxia is sensed 
throughout the tumour, carcinoma cells secrete exosomes into the 
microenvironment to start signalling and turn on the angiogenic switch to ensure 
adequate oxygenation [Giordano, 2001; Park, 2010]. Hypoxia-induced proteins 
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secreted by tumour exosomes are taken up by the normal host endothelial cells 
where the exosomal cargo stimulates new tubule formation which eventually leads 
to a network of blood vessels to supply that area [Skog, 2008]. Endothelial cells that 
have taken up hypoxic tumour exosomes start releasing growth factors and 
cytokines that stimulate pericytes through the PI3K/AKT pathway [Kucharzewska, 
2013]. 
In the early stages of cancer, the immune system may stop tumour 
progression however growing tumours can activate immune-suppressive pathways 
and evade immune surveillance. Exosomes produced by immune cells are able to 
initiate an anti-tumour immune response. Mast cell-derived exosomes can induce 
dendritic cell differentiation and activate T and B cells, whereas dendritic cell-derived 
exosomes sensitise other immune cells to tumour antigens [Skokos, 2003 andThéry, 
1999]. Tumour-derived exosomes are involved in immune escape by increasing 
myeloid progenitor cell differentiation, decreasing T cell proliferation and effect or 
functions and also by cancelling the natural cytotoxic responses controlled by 
natural killer cells [Valenti, 2007; Xiang, 2009]. 
The metastatic potential of the parent cell has been shown to affect particular 
characteristics of the exosomes that they release. In breast cancer cells, exosomes 
isolated from cells with the highest metastatic potential induced the largest increase 
in motility. These exosomes also induced migration to a degree that was dependent 
on the metastatic potential of the parent cell type. Exosomes derived from parent 
metastatic cell lines promoted cell mobility faster and/or to a further extent than 
exosomes isolated from non-metastatic cell lines or control media [Harris, 2015]. 
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Figure 1.5: The promotion of exosomes in cancer metastasis. Tumour-associated 
exosomes influence cells and modulate the microenvironment involving key steps in the 
cancer metastasis cascade. 1. In the primary site, tumour cells secrete exosomes to induce 
EMT and degrade the matrix. The Wnt pathway in cancer cells is also activated by 
exosomes during migration. 2. During intravasation, the endothelium is disturbed directly by 
tumour-secreted exosomes and indirectly by macrophages activated by exosomes from 
tumour cells. 3. Circulating tumour cells (CTCs) and tumour-activated platelets secrete 
exosomes affecting the immune cells and CTCs. 4. Adhesive molecules on endothelial cells 
are upregulated by exosomes from the adherent tumour cell. 5. Disseminated tumour cells 
provide a micrometastasis at an appropriate niche, remoulded by exosomes from the 
primary site [An, 2015]. 
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In the Kharaziha et al.(2015) study comparing docetaxel sensitive and 
resistant exosomes from DU145 cells, DU145 cells treated with 10 µg/mL of DU145-
Tax-res exosomes had a higher ability to degrade the extracellular matrix (ECM) 
compared to DU145 cells treated with either PBS or DU145-Tax-sen exosomes. The 
amount of degraded ECM, depicted as regions of matrix where fluorescein was 
degraded, was quantified and found to be higher in Tax-res exosome treated DU145 
cells than in the matrix of PBS or Tax-sen treated DU145 cells [Kharaziha, 2015]. 
The Src/PI3K/AKT and the Ras/Raf/MEK/ERK signalling cascades have been 
shown to be vital for the promotion of migration, invasion and metastasis [Kinkade, 
2008]. Whether or not the addition of Tax-res exosomes could modulate the active, 
phosphorylated levels of AKT and ERK1/2 was also investigated. There was no 
difference in AKT phosphorylation levels however there was an increase in the 
ERK1/2 phosphorylation levels. This data indicates that Tax-res exosomes may 
have the ability to promote migration and invasion in recipient PCa cells. It was also 
shown that the isolated exosomes from PCa patient sera could induce enhanced 
cell proliferation and invasion of the 22Rv1 and DU145 cell lines [Kharaziha, 2015; 
Corcoran, 2012]. 
 
1.3.7 GLUTATHIONE TRANSFERASES 
  There are three distinct families of human glutathione transferases (GSTs) 
including cytosolic, mitochondrial and membrane-bound microsomal groups. The 
cytosolic GSTs are differentiated into seven classes: alpha (α, A), mu (µ, M), omega 
(Ω, O), pi (π, P), sigma (σ), theta (θ, T) and zeta (Ζ) [Tew, 2011]. The different 
classes of mammalian GSTs differ in the chromosomal locations of their 
corresponding genes and their gene structure, resulting in distinct properties and 
protein structures [Hayes, 1995].The GST genes are found in human chromosomes 
at 11q for class GSTP1, 22q for GSTT1 and 1p for GSTM1. Cytosolic GSTs are 
dimeric and each protein chain is identical and depicted as Arabic numbers in the 
GST name i.e. GSTP1. Each subunit consists of two distinct domains which share 
common folds within classes. The two subunits are catalytically independent 
however the assembly of a dimeric GST is important to stabilise the enzymes. Both 
subunits are responsible for binding the physiological co-substrate glutathione 
(GSH) and the respective exogenous substrate at the active site [Reinemer, 1997]. 
The GST enzymes studied here - GSTP1, GSTT1, GSTM1 and GSTM3, are 
distinguished by the different residues responsible for their catalytic activity. For 
example, the pi (P) and mu (M) classes possess key tyrosine residues whereas the 
theta class (T) contain serine residues [Atkinson, 2009]. 
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 Functional GST enzymes exist as dimers of either identical (homodimers) or 
different (heterodimers) subunits, with subunit molecular weights ranging from 17 to 
28 kDa. The formation of heterodimers is restricted to subunits of the same class as 
monomers of different classes are unable to dimerise due to the incompatibility of 
the interfacial residues. Generally, members of the same class share more than 40-
50% sequence identity but have less than 25-30% sequence identity with GSTs of 
other classes [Tew, 2012; Board, 2013; Hebert, 2007]. 
 GSTs play a role in internal cell detoxification and were found to neutralise 
toxic effects caused by drugs, food additives, environmental chemicals and 
carcinogens [McElwee, 2007].The natural substrate of GST is glutathione which is a 
water-soluble molecule that is widely available in both the oxidised and reduced 
(GSHRed) forms in eukaryotes. The binding of GSHRed with GSTs causes oxidation of 
the substrate which in turn maintains the balance of redox states in cells [Liska, 
1998]. Internal detoxification by GSTs occurs in the conjugation pathway (Phase II) 
where GSTs bind with substrates forming conjugates, such as the GSH S-
conjugate. The conjugate is then catalysed to cysteine S-conjugate by γ-
glutamyltranspeptidase which is finally excreted in faeces and urine [Lash, 
1994;Kursula, 2005]. 
 
1.3.8 THE INVOLVEMENT OF GLUTATHIONE TRANSFERASES IN CELL  
SIGNALLING PATHWAYS 
 GSTP1 has been shown to play a role in cell signalling as it can inhibit c-Jun 
N-terminal kinase 1 (JNK1) by direct protein-protein interaction as seen in Figure 
1.5. JNK is a MAP kinase involved in stress response, apoptosis, inflammation and 
cellular differentiation and proliferation. Low JNK activity is observed in non-stressed 
cells due to the sequestration of the protein in a GSTP1:JNK complex [Adler, 1999]. 
The monomeric form of GSTP1 binds to the C-terminal of JNK and suppresses its 
kinase activity [Wang, 2001]. The dimeric form of GSTP1 (from two monomers) is 
demonstrated after the induction of apoptosis by hydrogen peroxide in 
neuroblastomas showing that the suppression of JNK activity is reversed under 
oxidative stress conditions. This leads to the dissociation of the GSTP1:JNK 
complex. By increasing the levels of monomeric GSTP1, the rebinding of GSTP1 to 
JNK occurs resulting in attenuation [Bernardini, 2002]. Mouse embryo fibroblast 
cells engineered to be null for GST expression were found to contain high basal 
levels of JNK activity which was reduced when these cells were transfected with 
GSTP1 cDNA [Chen, 2002]. 
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  In a human granulosa-like tumour cell line (KGN), the depletion of GSTT1 
inactivated the p38-MK2 signalling pathway and reduced apoptosis after exposure 
to hydrogen peroxide. MK2 (MAPK-activated protein kinase 2) is a downstream 
transporter of p38 and is involved in age-associated change in the subcellular 
localisation of p38 [Ito, 2011]. 
  GSTM1 is able to bind to apoptosis signal-reducing kinase 1 (ASK1) and 
inhibit its ability to activate the JNK and p38 signalling pathways [Cho, 2001]. ASK1 
is a Mitogen-activated protein kinase kinase kinase (MAPKKK) which activates both 
JNK and p38. TNF-receptor-associated factor 2 (TRAF2) and other TRAF proteins 
have been reported to interact with and activate ASK1 [Shiizaki, 2013]. This 
mechanism is similar to the one proposed for GSTP1:JNK. In an unstressed cellular 
environment, ASK1 shows low activity because of its sequestration via GSTM1. 
During conditions of oxidative or chemical stress, dissociation of the GSTM1:ASK1 
complex occurs, releasing GSTM1 for oligomerisation, then activating ASK1 and 
subsequently inducing apoptosis [Dorion, 2002]. Ovarian GSTM1 has been shown 
to be involved in negatively regulating ASK1 with the formation of protein complexes 
that dissociate during stress and lead to ASK1-induced apoptosis [Bhattacharya, 
2013].  
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Figure 1.6: Interactions between GSTP1 and GSTM1 isozymes and regulatory 
kinases implicated in the stress-signalling pathway. GSTs interact with several 
MAPKs in non-stressed conditions. Following exposure to reactive oxygen species (ROS), 
drugs and/or cytokines or UV radiation, protein complexes dissociate leading to the 
activation of signalling pathways. MAPK – Mitogen-activated protein kinase, JNK – c-Jun N-
terminal kinase, ASK1 – apoptosis signalling-regulating kinase 1, TRAF – TNF-receptor-
associated factor 2, EGFR – epidermal growth factor receptor, PKC – protein kinase C, PKA 
– protein kinase A [Adapted from: Singh, 2015]. 
 
1.3.9 THE INVOLVEMENT OF GLUTATHIONE TRANSFERASES IN THE 
PROGRESSION OF CANCER 
  GST over-expression has been observed in both in vitro and in vivo studies 
in a range of neoplastic cells. GST over-expression was observed in carcinogenesis 
and drug resistance, potentially allowing GSTs to be used as a marker protein for 
cancer progression. There is a lot of emphasis on GSTP1 as it is the most widely 
distributed and the most abundant isozyme. Its expression is mainly associated with 
the development and resistance of tumours against commonly used anti-cancer 
drugs [Oakley, 2011]. GST expression has been found to be upregulated at both the 
protein and mRNA level in a panel of 60 human tumour cell lines used in the NCI 
Drug Screening Program [Tew, 1996]. GSTP1 was also found to be the most 
predominant GST isozyme in these cancer cells. 
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 There have been many controversial studies regarding the over-expression or 
down-regulation of GSTP1 and its involvement in tumour progression. GSTP1 
positive cancer associated fibroblasts (CAFs) have been involved with GSTP1 
negative cancer cells in primary breast cancer and axillary lymph node metastases 
[Chaiwun, 2011]. In a significant number of cases, CAFs were positive for GSTP1 
expression. These GSTP1-positive CAFs in the tumour microenvironment may 
protect the GSTP1-negative cancer cells by catalysing GSTP1-mediated reactions 
that would neutralise chemotherapeutic agents [Chaiwun, 2011]. In a study 
examining the expression of drug resistance gene products in lung carcinoma 
progression, GSTP1 expression was elevated in tumour tissue compared to normal 
lung tissue. GSTP1 expression also increased with increasing tumour volume and 
differentiating grade. The results suggest that the level of GSTP1 in lung cells 
increases as cells progress from normal to a transformed state [Mattern, 2002]. In a 
separate study looking at the prognostic role that GSTP1 has in invasive breast 
cancer, it was concluded that GSTP1 expression could be an independent predictor 
of poor prognosis in breast cancer patients. Survival rates were worse in patients 
with GSTP1 positive breast tumours and the relative risk of tumour recurrence was 
also higher [Huang, 2003]. Alternatively, the absence of GSTP1 expression in 
human oesophageal squamous carcinoma was associated with a significantly 
shorter overall survival [Wang, 2010]. This correlates with the findings of prostate 
adenocarcinomas where the down-regulation of GSTP1 was observed and the loss 
of GSTP1 expression was associated with malignant transformation [Okino, 2009, 
Mavis, 2009]. 
  In breast cancer cells, GSTP1 enhanced proliferation and migration. 
Recombinant GSTP1 added to culture medium of human breast cancer cells bound 
directly to the cell surface and increased the viability, growth rate and migration of 
the cells [He, 2011]. 
  GSTP1 may influence cancer cell resistance to doxorubicin through the 
suppression of doxorubicin conversion to semiquinone free radicals and the 
subsequent production of superoxide anion radicals and peroxides [Finn, 2011]. 
Radiation kills cells by forming highly reactive oxygen radicals that damage tumour 
cell DNA and GSTP1 reduces these reactive oxygen radicals, making tumours 
resistant to radiotherapy [Kanwal, 2014]. This suggests that the over-expression of 
GSTP1 may be associated with the development of drug resistance in cancer cells, 
where it increases detoxification of the agents and also the suppression of cellular 
reactive oxygen species inducing apoptosis. 
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 Extensive studies have examined the relationship between single nucleotide 
polymorphisms (SNPs) of GST and null genotypes of GSTM1 and GSTT1 with 
susceptibility to prostate cancer. In an Asian population, a meta-analysis showed 
that GST polymorphisms may be able to predict disease susceptibility and the null 
GSTM1 allele could be associated with lower risk of prostate cancer but an 
increased risk of other cancers [Wei, 2012]. An opposing study has shown that 
polymorphisms may actually not be associated with disease outcome and any 
further possible recurrence [Wiklund, 2009] and in fact many of the studies 
regarding polymorphisms have inconsistent findings [Cotignola, 2009; Nock, 2009; 
Agalliu, 2006]. Epigenetic changes are changes in gene expression that aren’t 
caused by alterations in the primary sequence of the nucleotides of the gene. DNA 
hypermethylation is the most common epigenetic change and one of the most 
common molecular alterations in human cancers [Phé, 2010]. CpG dinucleotides are 
often found in clusters called CpG islands in promoter regions. CpG islands of many 
genes, including tumour suppressor genes, are unmethylated in normal tissues and 
often methylated to varying degrees in multiple cancer types which can cause gene 
transcription silencing and the inactivation of these tumour suppressor genes [Phé, 
2010; Chiam, 2014]. In prostate cancer, it has been found that the promotor regions 
of several genes were hypermethylated tested by methylation-specific PCR [Liu, 
2011; Ellinger, 2008; Bastian, 2005]. GSTP1 promoter hypermethylation is currently 
the best readily available DNA-based biomarker for prostate cancer tissues as it is 
only rarely present in benign prostate tissue [Phé, 2010]. A major issue with using 
this technique as a biomarker is that GSTP1CpG island hypermethylation has also 
been reported in other cancers so it is not specific to prostate cancer [Esteller, 
2001]. There is also evidence that GSTP1 methylation could trigger “epigenetic 
catastrophe” where tumour suppressor genes like APC and RAR-beta may also 
become hypermethylated [Yegnasubramanian, 2004].  
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Chapter 2: Research Design 
 
2.1 METHODOLOGY AND RESEARCH DESIGN 
 There were 3 main research aims for this project.  The first was to profile GST 
expression in prostate cancer cell lines using Reverse Transcriptase-PCR and 
Western analysis, then determine whether GST enzymes expressed by these cells 
appeared as cargo in exosomes that were released into the growth medium.  The 
second was to use a cell line that did not express a particular GST (as identified in 
Aim 1), over-express that GST in that cell line by cloning the complete coding 
sequence into the mammalian expression vector (pIRES-neo2) then determine 
whether the GST was subsequently packaged into exosomes. The effect of 
exogenous over-expression of the GST enzyme on in vitro cell growth 
characteristics was determined using a proliferation assay and GST-enriched 
exosomes were collected from medium and added to parental cells and stromal 
prostatic fibroblasts to determine whether GST enzymes delivered via exosomes to 
GST negative cells may alter growth of those cells. Finally, because GST enzymes 
are important in detoxification of drugs, the third aim was to (1) determine whether 
GST over-expression increased resistance to the common anti-prostate cancer 
chemotherapy docetaxel and (2) whether exosome delivery of GST enzymes to a 
GST negative line could also provide resistance to docetaxel. 
 
2.2 PROCEDURES 
 
2.2.1 CELL CULTURE  
Cell culture of various PCa cell lines (DU145, PC3, LNCaP and 22Rv1) and 
stromal prostatic fibroblast cells (WPMY-1) was vital to the study in order to collect 
exosomes from cell culture medium and to examine the contents of these 
exosomes. Prostate cancer cells were originally obtained from the American Type 
Culture Collection. Cultured cells were also used to produce cDNA for RT-PCR 
expression analysis and cloning, to make protein lysates for Western blotting, and 
were used in various functional studies. 
 
2.2.1.1 PREPARATION OF EXOSOME-DEPLETED FOETAL CALF SERUM 
 Equal volumes (19.25 mL) of foetal calf serum (Thermo Fisher Scientific, 
Victoria, Australia) and phenol-red free RPMI-1640 medium (Thermo Fisher 
Scientific) were combined and the mixture centrifuged at 101,000xg for 1 h.  The 
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supernatant was filtered through a 0.22 µm filter then centrifuged again at 
101,000xg for 16 h. All centrifugations were performed at 4°C with the Optima™ 
XPN ultracentrifuge (Beckman-Coulter, New South Wales, Australia). The 
supernatant was collected and stored at -30°C until used to make 5% exosome-
depleted FCS RPMI medium for culturing cells.  
 
2.2.1.2 CELL CULTURE OF PROSTATE CANCER CELL LINES 
 Prostate cancer cell lines including DU145, PC3, LNCaP and 22Rv1 were 
maintained in 5% exosome depleted FCS+RPMI. Cells were maintained in an 
incubator at 37°C, 5% CO2 in a humid environment. Cells were grown and 
maintained in either T-75 or T-175 flasks (Thermo Fisher Scientific). After reaching 
80-90% confluency, conditioned media was collected for exosome isolation and the 
cells washed carefully with phosphate buffered saline (PBS) for passaging. The PBS 
was then aspirated and cells detached from the bottom of the flask with 0.25% 
Trypsin (Thermo Fisher Scientific) with incubation at 37°C for 5 min. The trypsin was 
then inhibited by the addition of fresh exosome-depleted media, the cells removed 
from the flask and collected by centrifugation at 100 x g for 5 min.  The supernatant 
was aspirated and the cell pellet resuspended in fresh medium. Cells were then split 
1:8 and seeded into new T-75 or T-175 flasks and placed back into the incubator for 
continued cell passaging. Culture media was aspirated and replaced with fresh 
media 3 days after passaging and the cells grown for a further 24-48 h before the 
conditioned media was collected and cells passaged again. All conditioned media 
was stored at 4°C for 1 week until exosome isolations were performed. For all 
experiments described here, only cells passaged less than 40 times were used. 
 
2.2.2 PROTEIN ANALYSIS  
The GST profile in a range of PCa cell lines was vital to the study to see if 
specific GSTs were present in more aggressive PCa cells or in less aggressive PCa 
cells or in a variety of PCa cells. The presence or absence of GSTs in exosomes 
was also important to see whether or not the GST expression profile followed that of 
its parent cells or if it was inconsistent. 
 
2.2.2.1 PREPARATION OF TOTAL PROTEIN LYSATES 
 Prostate cancer cell lines were grown to >90% confluence before total 
protein lysates were made using M-PER mammalian protein extraction reagent lysis 
buffer (Thermo Fisher Scientific) supplemented with Protease Inhibitor mini tablets 
(Pierce, Thermo Fisher Scientific) and Phosphatase Inhibitor mini tablets (Pierce, 
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Thermo Fisher Scientific). Briefly, adherent cell monolayers were washed with ice-
cold Phosphate Buffered Saline (1X PBS is 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L 
Na2HPO4, 0.24 g/L KH2PO4 adjusted to pH 7.4 with HCl in dH2O). The PBS was 
removed before the addition of 1 mL M-PER buffer and the flask placed on a rocking 
platform for 30 min at 4°C. The bottom of the flask was then scraped with a rubber 
cell scraper and the lysate transferred to a 1.6 mL Eppendorf tube.  Lysate was 
passed through a 26 gauge needle then centrifuged at 21,130xg for 1 h at 4°C to 
remove insoluble proteins and any remaining cell debris. After centrifugation, the 
supernatant was carefully removed without disturbing the pellet and placed in a 
sterile 1.6 mL Eppendorf tube. Soluble protein concentration was determined using 
the BCA assay (Pierce, Thermo, Rockford, IL) with bovine serum albumin (BSA) 
diluted from 0.1 mg/mL to 3 mg/mL used to determine the standard curve. Lysates 
were then used immediately or stored at -80°C until required for future experiments. 
 
2.2.2.2 PREPARATION OF EXOSOME PROTEIN LYSATES 
 Isolated exosome samples were lysed directly from the PBS suspension (see 
Section 2.2.3.1 Exosome preparations from cell culture medium).Soluble protein 
concentration was determined using the BCA assay (Pierce, Thermo, Rockford, IL) 
with bovine serum albumin (BSA) diluted from 0.01 mg/mL to 1 mg/mL used to 
determine the standard curve. Lysates were then stored at -80°C until required for 
future experiments. 
 
2.2.2.3 WESTERN ANALYSIS  
Protein lysate samples (40 μg) and exosome samples (5 μg)for Western 
analysis were resuspended in1X SDS Loading buffer (4X SDS-Loading Dye is 0.25 
M Tris-HCl pH 6.8, 40% glycerol, 8% SDS, 0.01% Bromophenol Blue) with fresh β-
mercaptoethanol added to 5%, and the sample heated to 95°C for 5 min. Proteins 
were separated by electrophoresis using SDS-PAGE gels (4% stacking and 10% 
separating) at 150 V for 1 h and then transferred at 90 V for 90 min onto BioTrace™ 
NT nitrocellulose membrane (Pall, Pensacola, FL) using SDS-Transfer buffer (25 
mMTris, 190 mM glycine, 20% methanol, pH 8.5). The membrane was washed once 
in Tris buffered saline with Tween-20 (TBS-T is 8 g/L NaCl, 3 g/L Tris, 0.2 g/L KCl, 
0.1% Tween-20 pH 7.4) then blocked with 5% skim milk / TBST for 1 h at room 
temperature before being incubated with the primary antibody diluted in 5% skim 
milk / TBST on a rocker at 4°Covernight (Table 2.1). Membranes were washed 3 
times for 10 min each before bound primary antibodies were detected using 
horseradish peroxidase-labelled secondary antibodies diluted in 5% skim milk / 1X 
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TBST with incubation for 1 h at room temperature. Blots were washed again 3 times 
for 10 min each before detection of bound secondary antibody using LumiGLO® 
chemiluminescent substrate (Cell Signaling Technologies, Danvers, MA) with 
exposure to Hyperfilm ECL  X-ray film (Amersham, Parramatta) for 2 to 15 min. 
 
Table 2.1: Antibodies used for Western analysis of target protein expression 
in total protein and exosome lysates. 
Target protein Species and type of Ab Antibody company Dilution 
TSG101 mouse monoclonal Abcam, Australia 1:1,000 
GSTP1 rabbit polyclonal Proteintech, Chicago, USA 1:1,000 
GSTT1 rabbit polyclonal Proteintech, Chicago, USA 1:1,000 
GSTM1 rabbit polyclonal Proteintech, Chicago, USA 1:2,000 
GSTM3 rabbit polyclonal Proteintech, Chicago, USA 1:5,000 
GAPDH mouse monoclonal Abcam, Australia 1:10,000 
anti-rabbit IgG goat anti-rabbit IgG, 
HRP-conjugated 
Proteintech, Chicago, USA 1:5,000 
anti-mouse 
IgG 
horse anti-mouse IgG, 
HRP- conjugated 
Cell Signaling, Beverly, USA 1:5,000 
 
2.2.3 EXOSOME PREPARATIONS AND VISUALISATION 
Exosome preparations were vital to the study to examine the contents of the 
exosomes. The isolated exosomes required visual confirmation to ensure that the 
majority of the exosome preparations were in fact exosomes and not cellular debris. 
 
2.2.3.1 EXOSOME PREPARATIONS FROM CELL CULTURE MEDIUM 
 Conditioned medium was first centrifuged at 300xg for 10 min to pellet and 
remove viable cells then centrifuged again at 2,000xg for 20 min to remove dead 
cells. The supernatant was then collected and centrifuged at 10,000xg for 30 min to 
remove cell debris, filtered through a 0.22 µM filter to remove any large 
microvesicles, then the supernatant centrifuged at 101,000xg in an Optima™ XPN 
ultracentrifuge for 90 min to pellet the exosomes. The supernatant was discarded 
and the exosome pellet washed in 800 µL sterile Dulbecco’s Phosphate Buffered 
Saline (DPBS - Thermo Fisher Scientific) and centrifuged at 101,000xg for 2 h in an 
Optima MAX-XP centrifuge (Beckman-Coulter). All centrifugation steps were 
performed at 4°C.The wash solution was discarded and the exosome pellet 
resuspended in 100 µL of sterile DPBS. An aliquot of 5 µL was stored at -80°C for 
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transmission electron microscopy (TEM) and the remaining 95 µL either used 
immediately for quantitation and Western analysis or stored at -80°C for use in 
future experiments. 
 
2.2.3.2 VISUALISATION OF EXOSOMES USING TRANSMISSION ELECTRON 
MICROSCOPY  
The 5 µL exosome aliquots were thawed and applied to copper-coated 
Formvar/Carbon grids (200 mesh) and allowed to incubate for 5 min at room 
temperature before negatively staining with 5 µL uranylacetate for a further 5 min. 
The grids were then examined with a JEOL 1400 electron microscope at 80 kV at a 
range of magnifications from 12,000 X to 15,000 X magnification (Central Analytical 
Research Facility, QUT).  
 
2.2.4 EXPRESSION OF GST ENZYMES IN PROSTATE CANCER CELL LINES 
 To determine whether the over-expression of GSTs in PCa cells could also 
increase the level of GSTs in exosomes shed by those cells, the full length coding 
sequences of GSTP1 and GSTM1 were cloned, initially into pGEM-T Easy vector 
(Promega, Madison, WI), then subsequently into the mammalian expression vector 
pIRES-neo2 for constitutive expression in prostate cancer cells. Protein expression 
of the transfected cell lines is driven by the human cytomegalovirus immediate-early 
enhancer/promoter (CMV).  
 
2.2.4.1 PRIMER DESIGN 
 Primers were designed using the NCBI database for the GSTP1 and 
GSTM1genes for RT-PCR expression analysis and cloning.GSTT1 and GSTM3 
primers were also designed for RT-PCR expression analysis only. Primers to 
amplify the complete coding sequence of both GSTP1 (Genbank sequence 
NM_000852.3) and GSTM1 (Genbank sequence NM_000561.3) were designed to 
include restriction enzyme sites for directional cloning into the mammalian 
expression vector pIRES-neo2 (Clontech, Mountain View, CA).  Restriction enzyme 
NheI was included on the forward primer that spanned the start codon and BamHI 
was included on the reverse primer that spanned the stop codon (Table 2.2).Primers 
were manufactured by Sigma-Aldrich (Sydney, Australia) and restriction enzymes 
purchased from New England Biolabs (NEB, Ipswich, MA). 
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Table 2.2: List of primers used throughout the study including cloning primers 
and screening primers.  
Name Primer Sequence (5’ – 3’) Product Tm oC 
 Primers for RT-PCR expression analysis only   
GSTT1 F CATCGTGGATCTGATTAAAGG  
403bp 
 
60°C GSTT1 R AGCTCCGTGATGGCTATGAGG 
GSTM3 F GCTTTCATGTGCCGTTTTGAG  
184 bp 
 
65°C GSTM3 R CAGTTGTCCAGGTAGCTCTTCC 
PBGD F CTTTCCAAGCGGAGCCATGTCTGG  
377bp 
 
60°C PBGD R CATGAGGGTTTTCCCGCTTGCAGA 
 Primers for both RT-PCR expression analysis and 
cloning  
  
 
GSTP1 F 
GTCAGGCTAGCGCCACCATGCGGCCCTACACCGTGGT
C 
 
632bp 
 
60°C 
GSTP1 R ACGTCGGATCCCTAACCCTCACTGTTTCCCGTTGC 
 
GSTM1 F 
GTCAGGCTAGCGCCACCATGCCCATGATACTGGGGTAC
TGG 
 
656bp 
 
72°C 
GSTM1 R ACGTCGGATCCCTACTTGTTGCCCCAGACAGCCAT 
Green: NheI; pink: Kozak sequence; blue: BamHI; underlined: start codon. Primers were 
obtained from Sigma-Aldrich. 
 
2.2.4.2 RNA EXTRACTION 
 RNA was isolated from DU145, PC3, LNCaP and 22Rv1 cells with1 mL TRIzol 
Reagent (Thermo Fisher Scientific). Cells were scraped off the tissue culture flask 
with a rubber cell scraper and moved to 1.6 mL Eppendorf tubes then incubated at 
room temperature for 5 min. A 200 µL aliquot of chloroform was then added to each 
tube and the tubes shaken vigorously for 15 sec, incubated for 2-3 min at room 
temperature then centrifuged at 12,000xg for 15 min at 4°C. The solution separated 
into three layers and the top layer (aqueous phase) containing the RNA was moved 
to a new tube without disturbing the other layers. RNA was then precipitated using 
500 µL of isopropanol added to the aqueous phase then incubated for 10 min at 
room temperature and collected by centrifugation at 12,000xg for 10 min at 4°C. The 
supernatant was removed and 1 mL of 70% ethanol added and centrifuged at 
7,500xg for 5 min at 4°C. The supernatant was removed completely and the RNA 
pellet was dried before being resuspended in 30 µL of UltrapureTMDNase/RNase 
free distilled water (Invitrogen, Waltham, MA). The RNA concentration and purity 
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was determined using a Nanodrop1000 Spectrophotometer (Thermo Fisher 
Scientific). 
 
2.2.4.3 cDNA PREPARATION 
 Total RNA (2 μg) from each cell line was used for cDNA synthesis using 
Superscript III (Thermo Fisher Scientific).To this, 1 µL of random primers, 2 µg RNA, 
1 µL 10 mM dNTP mix was added to a 0.2 mL PCR tube and made up to 13 µL with 
Ultrapure™ water. The tube was then incubated at 65°C for 5 min and placed on ice 
for 1 min. The tube was briefly centrifuged and 4 µL 5x First-Strand Buffer, 1 µL 0.1 
M DTT, 1 µL RNaseOUT Recombinant RNase Inhibitor and 1 µL of SuperScript™ III 
RT was added. The reaction was mixed by gently pipetting up and down and 
incubated at 25°C for 5 min. The reaction was then incubated at 55oC for 30-60 min 
and then heat-inactivated at 70°C for 15 min. Three samples were made, 1 test and 
2 negative controls. The negative control samples consisted of a no enzyme control 
where the SuperScript™ III enzyme wasn’t added to the reaction to identify any 
genomic DNA contamination. The second control contained reverse transcription 
reagents only (no RNA control). 
 
2.2.4.4 POLYMERASE CHAIN REACTION AMPLIFICATION OF GSTs 
 The complete coding sequences of GSTP1 and GSTM1were amplified using 
the pair of primers specific to each gene (Table 2.2) in polymerase chain reactions 
with 1 μL of the cDNA as the template and amplification using MyFi™ DNA 
Polymerase (Bioline, Alexandria, NSW) in a 25 µL reaction following the 
manufacturer’s recommendations. For semi-quantitative RT-PCR of other GST 
genes, primers were also designed to GSTT1 and GSTM3 (Table 2.2). Primers for 
specific amplification of the housekeeping gene porphobilinogen deaminase (PBGD) 
were also used to confirm integrity of each cDNA sample. Cycling conditions 
included an initial denaturation cycle of 95°C for 2 min followed by 30-40 cycles of 
94°C for 30 sec, 60°C (GSTP1), 60°C (GSTT1), 72°C (GSTM1),65°C (GSTM3) or 
60°C (PBGD)for 30 sec, 72°C for 30 sec, with a final extension cycle of 74°C for 7 
min and were performed in a Mastercycler Pro (Eppendorf, Hamburg, Germany). 
PCR products were separated on 1% tris-borate agarose gels containing a  
1:40, 000 dilution of Ethidium Bromideat 115 V for 20 min(Thermo Fisher Scientific) 
and photographed using a Gel Doc system (Syngene, MD, USA). The Bioline 
HyperLadder 50 bp DNA molecular weight marker (Marker) was separated in the 
first lane of each gel and used to confirm approximate PCR product sizes 
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2.2.4.5 LIGATION OF GSTP1 AND GSTM1 INTO THE pGEMT-Easy VECTOR 
Following electrophoresis, the amplified PCR products corresponding to the 
GSTP1 and GSTM1 coding sequences were excised from the gel and purified using 
the Wizard® SV Gel and PCR Clean-Up System (Promega).  The PCR products 
were then ligated into the pGEMT-Easy vector (Promega) following the 
manufacturer’s protocol.  Reactions contained 1 µL vector, 1 µL T4 ligase, 1 µL 10 x 
ligase buffer and 7 µL of the insert and were incubated at 14°C overnight. 
 
2.2.4.6 HEAT SHOCK TRANSFORMATION INTO E. COLI AND SELECTION OF 
TRANSORMED COLONIES  
 Aliquots of chemically competent TOP10 E. coli was available in our 
laboratory.  A 100 µL aliquot of cells was thawed on ice then combined with 3 µL of 
the ligation reaction.  After a 20 min incubation on ice, the cells were heated to 42°C 
for 45 sec and then returned to ice for a further 2 min.  The cells were then 
resuspended in 400 µL of Luria-Bertani (LB) medium (1% Bacto-tryptone, 1% NaCl, 
0.5% Bacto-yeast, pH 7.5) and incubated at 37°C for 1 h in a 200 rpm shaking 
incubator. The transformed cells were then plated on LB Agar plates (LB medium 
with 1.5% Bacto-agar) supplemented with 1 mM X-gal (5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside), 1 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) and 1 
mM Ampicillin and grown overnight at 37°C. 
 
2.2.4.7 PREPARATION OF PLASMID DNA 
 Six white colonies were selected and individually inoculated in 5 mL LB 
medium supplemented with 1 mM Ampicillin and incubated overnight at 37°C with 
shaking at 200 rpm. Plasmids were purified from bacterial cultures using the 
Wizard®Plus SV Minipreps DNA Purification System (Promega) and the 
manufacturer’s protocol was followed. The purified plasmid DNA was then quantified 
using a NanoDrop and stored at 4°C. A double digest using restriction enzymes 
NheI and BamH Iwas performed to confirm the presence of the GSTP1 or GSTM1 
inserts prior to sequencing. Reactions were performed containing 1µg of plasmid 
DNA, 1 µL of 10 x Buffer, 1 µL of NheI, 1µL of BamHI and was made to 10 µL with 
DNase/RNase free water. This reaction was incubated for 1h at 37°C and the 
fragments separated by electrophoresis through a 1.0% agarose gel at 110V for 20 
min and photographed using the Gel Doc system (Syngene).  
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2.2.4.8 SEQUENCING OF CONSTRUCTS  
 pGEM-T Easy plasmids containing an insert of the appropriate size were 
chosen for sequencing of the insert. Inserts were sequenced fully on both strands. 
For each reaction, 800 ng of purified plasmid DNA was used with 6 pmol primer 
(either T7 or SP6 - Table 2.3) and the reaction volume adjusted to 12 µL with 
DNase/RNase free water. Sequencing was performed by the Australian Genome 
Research Facility (AGRF) at the University of Queensland, Brisbane, Australia. 
Identity of the sequences as GSTP1 or GSTM1 was confirmed by comparison to the 
reference sequence in the BlastN database (NM_000852.3 and NM_000561.3, 
respectively) and through alignment with this sequence using the Sequencher4.7 
Demo software package (Gene Codes, Ann Arbor, MI). 
 
Table 2.3:  Primers used for sequencing of GSTP1 and GSTM1 inserts in 
pGEM-T Easy and pIRES-neo2. 
Primers were obtained from Sigma-Aldrich. 
 
2.2.4.9 PRODUCTION OF THE pIRES-neo2 VECTOR  
 A glycerol stock of the pIRES-neo2 vector in E. coli JM109 was used to 
inoculate 8 mL of LB medium supplemented with 100 µg/mL Ampicillin and this was 
cultured overnight at 37°C in a shaking incubator at 200 rpm. Plasmid was isolated 
from this bacterial culture using the Wizard® Plus SV Minipreps DNA Purification 
System (Promega) and the manufacturer’s instructions and stored at -20°C until 
required. 
 
2.2.4.10 CLONING INTO THE pIRES-neo2 VECTOR  
GSTP1 and GSTM1 coding sequences were removed from the pGEM-T 
vector via a double digest of 1 µg of each construct with the restriction enzymes 
NheI and BamHI as previously detailed.  Similarly, 2 µg of the mammalian 
expression vector pIRES-neo2(Figure 2.1) was also digested with NheI and BamHI. 
The restriction digests were then electrophoresed into a 1.0% agarose gel at 115V 
for 20 min to separate the insert sequence from the pGEM-T plasmid sequence and 
Primer Name Vector Primer Sequence (5’ – 3’) 
T7 pGEM-T Easy TAATACGACTCACTATAGGG 
SP6 pGEM-T Easy ATTTAGGTGACACTATAG 
CMV F pIRES-neo2 CGCAAATGGGCGGTAGGCGTG 
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the small fragment of the pIRES-neo2 multiple cloning site from the rest of the 
vector. The bands corresponding to the GSTP1 and GSTM1 coding sequences and 
pIRES-neo2 were then excised from the gel using a sterile scalpel blade and the 
DNA purified from the gel slice using the Wizard® SV Gel and PCR Clean-Up 
System (Promega) following the manufacturer’s instructions.  The GSTP1 and 
GSTM1 coding sequences were then ligated into the pIRES-neo2 vector using T4 
DNA ligase (Promega).  In each 10 µL reaction, 1 µL pIRES-neo2 vector was ligated 
with 7 µL of GST insert in the presence of 1 µL T4 ligase and 1 µL 10x ligase buffer.  
After an overnight incubation at 14°C, 3 µL of the ligation was used to transform E. 
coli TOP10 cells by heat shock which were then spread onto LB agar plates 
supplemented with 100 µg/mL Ampicillin for growth and selection overnight at 37°C.  
As before, several individual colonies were then selected for plasmid isolation using 
the Wizard Plus SV Minipreps DNA Purification System (Promega). 
 
 
Figure 2.1: Vector map of the pIRES-neo2 vector and multiple cloning site. 
GSTP1 and GSTM1 inserts were cut out of the pGEM-T Easy vector and subsequently 
cloned into the pIRES-neo2 vector in the multiple cloning site (MCS). 
 
2.2.4.11 SEQUENCING OF CONSTRUCTS  
 The plasmid DNA samples containing the appropriate sized insert were 
selected after restriction analysis and 800 ng used in a sequencing reaction with 1 
µL of the CMV forward primer (Table 2.3). As before, sequencing was performed by 
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AGRF (UQ) and the identity of the sequences confirmed by BlastN and Sequencher 
4.7 alignments to the reference sequence of each gene. 
 
2.2.4.12 SITE-DIRECTED MUTAGENESIS 
 A site-directed mutagenesis (SDM) protocol was used to change an 
incorrect base in the GSTP1 sequence. Two overlapping SDM primers were 
designed (Table 2.4), containing the correct base at nucleotide +5 of the coding 
sequence, and these were used in a PCR reaction with the GSTP1 pIRES-neo2 
vector (pIRES-P1) as the template. Amplifications were again performed using 
MyFi™ DNA Polymerase in a 25 µL reaction that included 30 ng of purified DNA, 5 
µL of 5 x Buffer, 1 µL forward SDM primer, 1µL reverse SDM primer, 1 µL MyFi™ 
DNA Polymerase, adjusted to 25 µL with Ultrapure™ distilled water. Cycling 
conditions included an initial denaturation at 95oC for 2 min, then 19 cycles of 95oC 
for 30 sec, 65oC for 30 sec and 72oC for 6 min (1 min per kb), with a final extension 
step at 74oC for 10 min. 
 
Table 2.4: List of site-directed mutagenesis primers. 
Site-Directed 
Mutagenesis  
Primers 
Primer Sequence (5’ – 3’) 
GSTP1 - SDM F GTCAGGCTAGCGCCACCATGCCGCCCTACACCGTGGTCTATT 
GSTP1 - SDM R AATAGACCACGGTGTAGGGCGGATGGTGGCGCTAGCCTCAG 
Primers were obtained from Sigma-Aldrich. 
 
Template plasmid in the PCR reaction product was then linearised by the direct 
addition of 1 µL of methylation sensitive restriction enzyme DpnI and incubation at 
37°C for 1 h. E. coli TOP10 cells were then transformed with 10µL of the DpnI-
digested PCR reaction using the heat shock protocol and plated on LB Agar-
Ampicillin plates.  Plasmids were isolated from several individual colonies, the 
presence of the insert confirmed by restriction digestion and the insert then 
sequenced at AGRF to confirm the base change. 
 
2.2.5 STABLE TRANSFECTION OF 22Rv1 CELLS WITH GSTP1 AND 
GSTM1EXPRESSION VECTORS 
 Expression constructs containing GSTP1 and GSTM1 coding sequences 
(pIRES-P1 and pIRES-M1, respectively) and the empty vector containing no insert 
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(VO) were used to transfect prostate cancer cell line 22Rv1 to create a model for 
studying GST loading into exosomes. 
 
2.2.5.1 LINEARISATION OF GST EXPRESSION CONSTRUCTS AND CO-
PRECIPITATION 
 The pIRES-P1, pIRES-M1 and pIRES-neo2 vectors (6 µg) were linearised 
by digestion with NruI at 37°C for 1 h. The linearised plasmid was then precipitated 
by adding 1/10th of the reaction volume of 3M sodium acetate, pH 5.2, and 3 
volumes of ice-cold 100% ethanol.  Precipitation was optimised by placing the 
samples at -80°C for 1 hour before collecting DNA using centrifugation at 15,000 
rpm for 30 min at 4°C. The supernatant was removed and the DNA pellet washed 
using 200µL of ice-cold 70% ethanol with a second centrifugation at 15,000 rpm for 
5 min at 4°C.  The 70% ethanol wash solution was then removed and the pellet 
dried thoroughly before being resuspended in Opti-MEM® medium (Thermo Fisher 
Scientific) for transfection.  
 
2.2.5.2 TRANSFECTION OF pIRES-neo2 CONSTRUCTS 
 Two six well plates were seeded with 22Rv1 cells to 60-80% confluency 
and the cells allowed to attach overnight under normal cell culture growth conditions. 
Cells were then transfected with either the linearisedpIRES-P1, linearised pIRES-M1 
or linearised pIRES-neo2 (vector only, VO) using Lipofectamine® 2000 (Thermo 
Fisher Scientific).  Briefly, for each reaction, 6µL of Lipofectamine® 2000 reagent 
was diluted in 150 µL Opti-MEM® Medium in a sterile Eppendorf tube and 
separately, 2.5 µg of DNA was resuspended in 150 µL of Opti-MEM® Medium in a 
second tube.  Diluted DNA was then added to the tube containing the diluted 
Lipofectamine® 2000 reagent slowly and gentle mixing by rotating the tube.  After 5 
min incubation at room temperature, 100 µL of the DNA-lipid complex was added to 
the cell growth medium in two duplicate wells and the medium swirled gently to mix. 
As a control, a mock transfection was performed using a sample to which no DNA 
was added. Transfected cells were then incubated under normal growth conditions 
for 4 h before changing medium to RPMI with 5% exosome-depleted FCS.  Cells 
were grown for 24-48 h before starting selection of stably transfected cells. 
 
2.2.5.3 SELECTION OF TRANSFECTED CELLS 
 Stably transfected 22Rv1 cells were selected by resistance to G418.  G418 
was added to exosome-depleted medium at a final concentration of 1.5 mg/mL and 
this was used for culture of transfected 22Rv1 cells with regular changes every 3-4 
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days for 2 weeks until the mock transfected cells had all died and colonies were 
seen growing in the wells containing cells transfected with the expression constructs 
pIRES-M1 and VO. Cells transfected with pIRES-P1 could not be generated despite 
several attempts. 
 
2.2.5.4 MAINTENANCE AND CRYOPRESERVATION OF TRANSFECTED CELLS 
 After selection, the transfected cells were expanded and samples 
cryopreserved. Cells were removed from the flask by trypsin digestion and 
passaged at a 1:6 split ratio into new flasks for continued cell culture.  For long term 
storage, samples of 700 µL of cells suspended in 5% exosome-depleted FCS 
growth medium were combined with 200 µL of fresh exosome-depleted FCS and 
100 µL of 100% dimethyl sulphoxide (DMSO) in 1.2 mL cryovials and slowly cooled 
to -80°C in a Mr Frosty Freezing container (Thermo Fisher Scientific). Cells were 
then stored in liquid nitrogen vapour until required. 
 
2.2.6 FUNCTIONAL STUDIES 
 A variety of functional studies were performed to determine the effect of 
GSTM1 expression on the growth characteristics of the transfected 22Rv1 cells. 
Exosomes released from 22Rv1 transfected cells were examined for GSTM1 
loading.  The effect of GSTM1-loaded exosomes on the growth of normal prostatic 
fibroblast cell line, WPMY-1 was also tested. 
 
2.2.6.1 CELL PROLIFERATION ASSAY 
 The proliferation of transfected cells (pIRES-M1 and VO) was compared to 
parental 22Rv1 cells using the colorimetric CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay (Promega). Cells were lifted from the tissue culture flask using 
trypsin, counted with a cell counter (BioRad, Gladesville, NSW), and diluted to 2 x 
105 cells/mL before 2000 cells were seeded into individual wells of  96-well cell 
culture plates in 100  µL of  RPMI containing 5% exosome-depleted FCS. Cells 
were grown under normal cell culture conditions for 4, 24 and 72 h after seeding. At 
each time point, 20 µL of Aqueous One Solution was added directly to the wells and 
the reaction incubated at 37°C for 1 h prior quantitation of the formazan product by 
measuring the absorbance at 490 nm on a Multiskan™ GO Microplate 
Spectrophotometer (Thermo Fisher Scientific). Proliferation of 22Rv1 exosome- 
andM1 exosome-treated WPMY-1 cells was also examined using the same method 
and compared to proliferation of untreated WPMY-1 cells.  
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2.2.7 DOCETAXEL TREATMENT OF PROSTATE CANCER CELL LINES 
 GSTs are involved in detoxifying chemotherapeutic agents and treatments 
with such agents may affect the level of GSTs that are present in PCa cells and the 
exosomes these treated cells shed. Dose-response curves were made to determine 
the IC50 of each cell line so a clinically appropriate concentration of Docetaxel would 
be used in functional studies that examine whether or not GSTM1 loaded exosomes 
could have a positive or negative effect on prostate cancer and stromal prostatic 
fibroblast cell lines. 
 
2.2.7.1 DOSE-RESPONSE CURVES OF PROSTATE CANCER CELL LINES 
 DU145, PC3, LNCaP and 22Rv1 cells were seeded into 96 well plates at 
different seeding densities for the cell line - DU145 at 5,000 cells/well, PC3 at 8,000 
cells/well, LNCaP at 10,000 cells/well and 22Rv1 cells at 5,000 cells/well. The 
densities were based on how confluent the monolayer was after a 24 h incubation. 
Cells were treated with Docetaxel diluted to various concentrations - 0.1, 1, 5, 10, 20 
and 40nM in 5% exosome-depleted FCS RPMI growth medium.  Cell proliferation 
was quantitated at two different time points, 24 and 72 h using the CellTiter 96® 
Aqueous One Solution Cell Proliferation Assay (Promega). Wells containing LNCaP 
cells were pre-coated in poly-L-lysine to ensure cell adherence.  
 
2.2.7.2 MEASURING PROLIFERATION OF PROSTATE CANCER CELLS AFTER 
CO-CULTURING WITH DOCETAXEL AND GSTM1 EXOSOMES 
DU145, PC3, LNCaP, 22Rv1 and WPMY-1 cells were seeded into 96 well 
plates at various seeding densities - DU145 at 5,000 cells/well, PC3 at 8,000 
cells/well, LNCaP at 10,000 cells/well, 22Rv1 cells at 5,000 cells/well and WPMY-1 
at 5, 000 cells/well. A range of controls were used including: a vehicle control 
(0.01% DMSO), cells treated with 100and 200 µg/mL 22Rv1-VO exosomes and 
cells treated with 20 nM Doc only. The test cells were treated with both 20 nM Doc 
and 100 or 200µg/mL 22Rv1-VO exosomes as well as treating with 20 nM Doc and 
100 or 200µg/mL 22Rv1-M1 exosomes. Cell proliferation was quantitated at 3 
different time points, 0, 24 and 72 h using the CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay (Promega). Wells containing LNCaP cells were pre-coated 
in poly-L-lysine to ensure cell adherence. 
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Chapter 3: GST enzymes are present in Prostate 
Cancer cells and shed exosomes 
 
3.1 INTRODUCTION 
In recent years, considerable scientific focus has turned to the study of 
exosomes, endosomal-derived microvesicles with diameters of 20-120 nm, with 
potential roles in communication, modulation of the immune system and preparation 
of the tumour microvenvironment prior to dissemination of metastatic cells 
[Mathivanan, 2010; Colombo, 2014; Greening,  2015; Webber, 2015]. Exosomes are 
released from many different cells in the body, including both normal and tumour 
cells, but their cargo of proteins, RNA sequences (miRNA, lncRNA) and genomic 
DNA often reflects their cell of origin, and they are therefore considered a potential 
source of biomarkers for diagnosis and prognosis of diseases including prostate 
cancer [Giusti  and Dolo,  2014]. In patients with prostate cancer, exosomes can be 
isolated from bodily fluids including plasma, seminal fluid, saliva and urine using 
centrifugation and antibody-enrichment methods [Bjinsdorp, 2013; Duijvesz, 2015; 
Zheng, 2014; Jia, 2014; Taylor and Shah, 2015].  
Extracellular vesicles released from the normal prostate also include 
prostasomes, reported to differ from exosomes in their biogenesis, size and their 
membrane structure. They range from 50 to 500 nm diameter, have a cholesterol- 
and sphingomyelin-rich lipid multilayer in comparison to the more simple lipid bilayer 
of exosomes [Poliakov, 2009].  Prostasomes also have a demonstrated function in 
normal processes of human reproduction, releasing ATPase which increases the 
motility of spermatozoa and delaying the acrosomal reaction to progesterone via the 
membrane cholesterol [Stegmayr and Ronquist, 1982; Cross and Mahasreshti, 
1997].  They also appear to protect sperm from phagocytosis by the immune cells of 
the female reproductive system through an immunosuppressive activity [Kelly, 1991; 
Poliakov, 2009].  
The largest cancer-derived extracellular vesicles are the oncosomes, atypical 
vesicles of 1-10 μm in diameter that form from non-apoptotic blebbing of the plasma 
membrane [Al-Nedawi, 2008]. Di Vizio et al. (2012) reported an increase in the 
number of large oncosomes present in the circulation of patients with metastatic 
prostate cancer.  
Glutathione-S-transferases (GSTs) are a family of related proteins important for 
internal cell detoxification of toxic secondary metabolites formed during oxidative 
stress agents via the enzymatic conjugation of glutathione (GSH) [Hayes, 2005; 
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McIlwain, 2006].  Conjugation of GSH with target compounds mostly results in the 
formation of inactive products that are pumped from the cell. In this way, GST 
enzymes expressed by cancer cells can neutralise the toxic effects of electrophilic 
chemotherapeutic drugs including taxanes that generate reactive oxygen species in 
cancer cells, and facilitate drug elimination through the ABC transporter MRP1 
[Reinemer, 1997; McElwee, 2007].  Resistance to the key chemotherapeutic agent 
Docetaxel (Taxotere™, Sanofi–Aventis, Paris, France), a taxoid derivative used 
against many solid tumours, including advanced castrate-resistant and/or metastatic 
prostate cancers, correlates with increased expression and catalytic activity of 
GSTP1 [Park, 2002]. In rare cases however, the GSH-conjugate formed may even 
be more reactive than the parent compound contributing to development of cancer 
through cell and DNA damage.  GSTT1, expressed at high levels in the prostate, 
has been linked to the formation of genotoxic intermediates that increase prostate 
cancer risk in this way [Sherratt, 1997].  Similarly, GSTM1 is also expressed in the 
prostate but its potential contribution to prostate cancer has not been explored in 
detail.  
The hypothesis of this study is that detection of these four cytosolic GST 
enzymes, GSTP1, GSTT1, GSTM1 and GSTM3 within microvesicles shed from 
prostate cancer cells may 1) assist in screening of patient fluid samples for the 
diagnosis of prostate cancer and 2) identify those cancers with increased risk of 
developing resistance to chemotherapeutic agents like docetaxel.  To explore this 
hypothesis, GSTP1, GSTT1, GSTM1 and GSTM3 expression profiles were firstly 
examined in prostate cancer cell lines using RT-PCR and their protein profiles 
correlated with gene expression using Western blot analysis.  Microvesicles were 
then prepared from the medium of cultured prostate cancer cell lines and their 
isolation verified with Western analysis and transmission electron microscopy. 
Which GST proteins were present within microvesicles released from different 
prostate cancer cell line cells was then determined using Western blot analysis. 
Finally, an over-expression approach was used to determine whether exogenously 
over-expressed GST enzymes could be loaded into microvesicles produced by 
GST-naïve prostate cancer cells.   
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3.2 MATERIALS AND METHODS 
 The common materials and methods relevant to this chapter have been outlined 
in Chapter 2. 
 
3.3  RESULTS 
 
3.3.1 EXPRESSION OF GSTP1, GSTT1, GSTM1 AND GSTM3 GENES IN 
PROSTATE CANCER CELL LINES 
 Reverse transcriptase polymerase chain reaction (RT-PCR) was used to 
determine the expression profile of GST enzymes in prostate cancer cell lines to 
select model cell lines for use in the study. RNA was extracted from >90% confluent 
monolayers of prostate cancer cell lines DU145, PC3, LNCaP and 22Rv1 cells then 
reverse transcribed into cDNA. This cDNA was then used as the template in PCR 
reactions with primer pairs designed to specifically amplify a PCR product 
corresponding to the individual GST enzymes GSTP1, GSTT1, GSTM1 and GSTM3 
and PBGD as a housekeeping control. PCR products were separated by agarose 
gel electrophoresis, visualised by staining with Ethidium Bromide and the size of the 
product estimated by comparison to a DNA molecular weight marker (Figure 3.1). 
Amplification of the housekeeping control PBGD was used to confirm the integrity of 
the cDNA from each cell line with an amplified product seen in the appropriate 
lanes. All negative controls contained no amplified product as expected.  A strongly 
staining band corresponding to GSTP1 was present in the lanes for cell lines 
DU145, PC3, LNCaP but this band stained only faintly in the lane for 22Rv1 cells.  
This suggests that GSTP1 is robustly expressed in DU145, PC3 and LNCaP but is 
only poorly expressed in 22Rv1. The GSTT1 gene was expressed by all cancer cell 
lines but as this band stained only very faintly this result would suggest that the 
gene is not highly expressed in any of these lines (Figure 3.1). The GSTM1 gene 
was expressed in DU145, PC3 and LNCaP cells and did not appear to be expressed 
by the 22Rv1 cell line. GSTM3 appeared to be highly expressed by all of the cell 
lines. 
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Figure 3.1: Expression profile of GST enzymes in prostate cancer cell lines 
using RT-PCR. A PCR product corresponding to the GSTP1 cDNA sequence was present 
in samples from  DU145, PC3, LNCaP and faintly in 22Rv1 cell lines at the expected size of 
632 bp.GSTT1 was seen in DU145, PC3, LNCaP and 22Rv1 cells with an expected size of 
403 bp.GSTM1 was present in DU145, PC3 and LNCaP cell lines at 656  bp and GSTM3 in 
all prostate cancer cell lines at 184bp. Various controls including a reaction with no reverse 
transcriptase (RT -ve), another with no RNA (RNA -ve) and a non-template control (PCR -ve) 
were included with each PCR. PBGD was used as a housekeeping gene which was present 
in samples from all of the prostate cancer cell lines at 377 bp. The Bioline HyperLadder 50 
bp DNA molecular weight marker (Marker) was separated in the first lane of each gel and 
used to confirm approximate PCR product sizes. 
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3.3.2 EXPRESSION OF GSTP1, GSTT1, GSTM1 AND GSTM3 PROTEIN IN 
PROSTATE CANCER CELL LINES 
To determine whether protein expression levels correlated with gene 
expression, total protein lysates were prepared using the same prostate cancer cell 
lines and separated using reducing SDS-PAGE then transferred to nitrocellulose for 
Western blot analysis using antibodies specific to each of the four selected GST 
enzymes. A strong immunoreactive band corresponding to GSTP1 at the predicted 
molecular weight of 23 kDa was seen in the lanes corresponding to DU145 and PC3 
but was only very faint in LNCaP and absent in 22Rv1 (Figure 3.2A). GSTT1 was 
identified at the monomeric size of 27 kDa in all prostate cancer lysates (Figure 
3.2B). GSTM1 was identified as a band at 55 kDa in the LNCaP protein sample with 
no band consistent with the monomer of 27 kDa seen in any of the samples (Figure 
3.2C and data not shown).  Given that samples were denatured by boiling and 
reduced with -mercaptoethanol, it is likely that this 55 kDa band is dimeric GSTM1 
and the two monomers in this are covalently linked through interactions other than 
disulphide bridges. The expression pattern of GSTM3 was similar to that of GSTT1, 
with more protein detected in the DU145 and PC3 cell lines when compared with 
LNCaP and 22Rv1, although GSTM3 was also detected in these cell lines as a band 
of much lower intensity when related to GAPDH (Figure 3.2D).  An antibody to the 
housekeeping control GAPDH confirmed even protein loading in Westerns (Figure 
3.2 A, B, C) with a clear immunoreactive band identified at 37 kDa in each lane and 
of a similar intensity.    
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Figure 3.2: Western blot images comparing GST content in prostate cancer 
whole cell lysates. The proteins of interest, GSTP1, GSTT1, GSTM1 and GSTM3 were 
examined in total protein lysates from four prostate cancer cell lines as indicated. Detection 
of GAPDH using a specific antibody was used as a control for each lysate and even loading 
of protein is indicated by consistent immunoreactivity seen at 37 kDa in the lower panels. (A) 
A single band was detected using an antibody specific to GSTP1 at the monomeric size of 
23 kDa and was present in the DU145, PC3 and faintly in the LNCaP lysates. (B) A single 
band was detected using an antibody specific to GSTT1 in all of the prostate cancer lysates 
at the monomeric size of 27 kDa. (C) A single band was detected using an antibody specific 
to GSTM1 only in LNCaP lysates and as a dimeric protein at 55 kDa. (D) A single band was 
detected using an antibody specific to GSTM3 and was present in all of the lysates at the 
monomeric size of 27 kDa.  
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3.3.3 PROSTATE CANCER CELL LINES PRODUCE EXOSOMES AND 
PROSTASOMES UNDER NORMAL CELL CULTURE CONDITIONS 
Prostate cancer cells release microvesicles that range in size from 30 nm to 
10 µm and for this reason ultracentrifugation was chosen as the method of 
microvesicle isolation for this study, despite the increased risk of collection of 
contaminating cellular debris.  Prostate cancer cell lines were grown in medium 
supplemented with foetal calf serum that had been depleted of any bovine 
microvesicles using a validated ultra-centrifugation protocol [Théry, 2006].  Medium 
was removed from the cell culture flasks in which various prostate cancer cell lines 
were growing and microvesicles isolated from this using the method described in 
Chapter 2 (Method 2.2.3 – Exosome preparations and visualisation). Microvesicles 
are 30 – 120 nm in diameter and in each preparation, vesicles with diameters that 
fall within this range can be clearly identified but these microvesicles do vary in size 
and interestingly, there also appears to be two clear subsets of exosomes that can 
be separated depending on their size – small exosomes with an average diameter of 
40 nm (range 20 nm to 80 nm) and large exosomes with an average diameter of 100 
nm (range 80 nm to 120 nm). In addition, several much larger microvesicles can 
also be seen and because these larger vesicles have an average diameter of 200 
nm (range >120 nm to 250 nm) these are most likely prostasomes (reported 
diameters between 50 and 500 nm). No microvesicles larger than this (eg. 
oncosomes of 1 – 10 µm) were identified but due to their much larger size these 
may have been removed from the exosome purification process during removal of 
cellular debris. In all microvesicle preparations, vesicles of different sizes can be 
seen, some of which have the cup-shaped morphology characteristic of 
microvesicles prepared for TEM. Figure 3.3 shows vesicles that were shed from 
each prostate cancer cell line and the summary of these results is shown in Table 
3.1.DU145, PC3 and LNCaP cells shed exosomes (averaging 30-120 nm in 
diameter) whereas 22Rv1 cells shed larger vesicles, the prostasomes (averaging 
150 nm in diameter). 
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Figure 3.3: Transmission Electron Microscopy image of microvesicles isolated 
from conditioned medium. Conditioned medium was collected from prostate cancer 
cells after 24 h of incubation and differentially centrifuged to remove cellular debris. The 
microvesicles were then resuspended in DPBS and analysed by TEM using a negative 
staining method with 1% uranyl acetate with the microscope operating at 80 kV. The 
microvesicles appear spherical and cup shaped ranging from 20-250 nm. (A) DU145 derived 
microvesicles ranged from 20-200 nm at 12,000X magnification. (B) PC3 derived 
microvesicles ranged from 40-230 nm at 12,000X magnification. (C) LNCaP derived 
microvesicles ranged from 40-230 nm at 15,000X magnification. (D) 22Rv1 derived 
microvesicles ranged from 40-150 nm at 12,000X magnification. A scale bar indicating 500 
nm is shown for each image.  
A B 
C D 
DU145 PC3 
LNCaP 22Rv1 
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Table 3.1: Quantitation of microvesicles (exosomes and prostasomes) in one TEM grid from conditioned media of prostate cancer cell 
lines based on diameter. 
  
Table 3.1 summaries the different types and sizes of vesicles that were found from each prostate cancer cell line. DU145 and LNCaP cells 
mostly shed small exosomes whereas PC3 cells shed mostly large exosomes. 22Rv1 cells released an average number of small and large 
exosomes however they also shed more prostasomes than the other cell lines. 
 
Cell line Total Number of 
Small 
Exosomes 
Average 
diameter 
and range 
% of 
total 
Number of 
Large 
Exosomes 
Average 
diameter and 
range 
% of 
total 
Number of 
Prostasomes 
Average 
diameter and 
range 
% of 
total 
DU145 44 23 30 nm 
20 - 80nm 
52% 17 120 nm 
80 - 120 nm 
39% 4 200 nm 
120 - 250 nm 
9% 
PC3 23 7 40 nm 
20 - 80 nm 
30% 12 110 nm 
80 – 120 nm 
52% 4 230 nm 
120 – 250 nm 
17% 
LNCaP 23 15 40 nm 
20 - 80 nm 
65% 4 100 nm 
80 – 120 nm 
17% 4 230 nm 
120 – 250 nm 
17% 
22Rv1 47 17 40 nm 
20 - 80 nm 
36% 18 120 nm 
80 – 120 nm 
38% 12 150 nm 
120 – 250 nm 
25% 
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3.3.4 MICROVESICLES RELEASED FROM PROSTATE CANCER CELLS IN 
CULTURE CONTAIN GST ENZYMES 
The TEM results indicated the presence of microvesicles and this was further 
verified with Western blot analysis to detect the exosome associated protein 
TSG101. Prepared microvesicles resuspended in DPBS were lysed using M-PER 
mammalian lysis buffer and the proteins separated by SDS-PAGE before being 
transferred onto nitrocellulose membranes. The membranes were then 
immunoblotted using antibodies specific to TSG101 and a single immunoreactive 
band was identified in all exosome samples at the predicted molecular weight of 48 
kDa (bottom panels in Figure 3.4). TSG101 often appears highly enriched in 22Rv1 
preparations most likely due to the differences in exosome biogenesis for the 
different cell lines which was also seen in another study [Yoshioka, 2013].   
To determine whether microvesicles released from prostate cancer cells 
contain GST enzymes, exosome preparations were also examined by Western blot 
analysis using antibodies specific to each of the four chosen GST enzymes (Figure 
3.4). Expression of TSG101 was used as a positive control for exosomes. 
Consistent with the expression of GSTP1 protein in prostate cancer cell lysates, a 
single band at 23 kDa, the predicted size of monomeric GSTP1, was detected in 
microvesicle preparations from DU145 and PC3 but not in LNCaP or 22Rv1 
preparations (Figure 3.4A). Although the GSTT1 protein was consistently present in 
all cell lysates at the monomeric size of 27 kDa, no GSTT1 protein was detected in 
exosomes from any of the four prostate cancer cell lines (Figure 3.4B).GSTM1 was 
detected in microvesicle preparations from LNCaP consistent with the high 
expression seen in the Western analysis of LNCaP total protein lysate (compare 
Figure 3.2C with Figure 3.4C).  The size of the protein bands detected in these 
samples were however different.  GSTM1 in the LNCaP total protein lysate was 55 
kDa and is most likely dimeric protein but the GSTM1 protein in the LNCaP 
exosomes was present at 27 kDa and is probably the monomeric form.  The 
Western analysis of LNCaP exosomes also detected a band at 75 kDa but the 
identity of this band is unknown and this was not detected in the LNCaP total protein 
lysate.  Similarly, DU145 exosomes also appear to contain monomeric GSTM1 
protein despite having undetectable expression in the total protein lysate sample 
tested previously (compare Figure 3.2C with Figure 3.4C). The higher molecular 
weight band at 75 kDa is also detected in the DU145 exosome sample.  GSTM1 
expression was not seen in PC3 and 22Rv1 samples, and this is consistent withthe 
result gained using total protein lysates. GSTM3 was present in all of the lysates at 
the monomeric size of 27 kDa, however similarly to GSTM1, it was only present in 
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the DU145 and LNCaP exosome preparations at 27 kDa (Figure 3.4D). The 
comparison between lysate and exosome content is highlighted in Table 3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Western blot images comparing GST content in exosome 
preparations shed from prostate cancer cells. The GST proteins of interest, GSTP1, 
GSTT1, GSTM1 and GSTM3 were examined in exosome preparations. Exosome marker 
TSG101 was used as an exosome marker for each sample and a single band of the correct 
molecular weight (48 kDa) was present in all exosome preparations - seen in the lower 
panels. (A) A single band corresponding to GSTP1 was present in the DU145 and PC3 
preparations at the monomeric size of 23 kDa. (B) No bands corresponding to GSTT1 
(predicted molecular weight of 27 kDa) were present in any of the exosome preparations 
from the prostate cancer cells. (C) Two immunoreactive bands were seen in the Western bot 
analysis using a GSTM1 specific antibody but only in the DU145 and LNCaP exosome 
preparations.  One was at the monomeric size of 27 kDa but a second was identified at 75 
kDa and the identity of this band is unknown (?). (D) An immunoreactive band corresponding 
to GSTM3 was present in only the DU145 and LNCaP exosome preparations and was at the 
predicted monomeric size of 27 kDa.   
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Table 3.2: Visual comparison of GST enzymes found in whole cell lysates and 
exosome preparations relative to loading controls. 
 
Cell 
lines 
GST 
enzyme 
Level of expression in 
total cell lysate 
Level of expression in 
exosome lysate 
DU145 GSTP1 +++ +++ 
 GSTT1 ++ ND 
 GSTM1 ND ++ 75 kDa; + 27 kDa 
 GSTM3 ++ +++ 
PC3 GSTP1 +++ +++ 
 GSTT1 ++ ND 
 GSTM1 ND ND 
 GSTM3 ++ ND 
LNCaP GSTP1 + ND 
 GSTT1 + ND 
 GSTM1 +++ 55 kDa ++ 75 kDa; +++ 27 kDa 
 GSTM3 + +++ 
22Rv1 GSTP1 ND ND 
 GSTT1 + ND 
 GSTM1 ND ND 
 GSTM3 + ND 
+++ - strongly expressed, ++ - expressed, + - weakly expressed, ND – not detected. 
 
Table 3.2 summarises the different levels of GST expression in lysates compared to 
exosomes. This summary was performed visually based off a number of different 
western blotting results for both the lysates and exosome preparations. 
 
3.3.5 LOADING OF GST ENZYMES INTO PROSTATE CANCER 
MICROVESICLES 
Comparison of GST enzyme levels in total protein lysates and microvesicles 
(Table 3.2) suggested that in some cases GSTs may be preferentially loaded into 
exosomes (eg. GSTM1 and DU145 - low lysate level but high exosome level).  To 
determine whether increasing GST expression in a naïve cell also increases the 
GST enzyme in shed exosomes, the complete coding sequences of GSTP1 and 
GSTM1 were cloned into the mammalian expression vector pIRES-neo2 to create 
expression constructs suitable for the stable transfection of the prostate cancer cell 
line 22Rv1 that does not express either of these two GST enzymes. Integrity of the 
coding sequences was confirmed by sequencing fully on both strands and in the 
course of this a single nucleotide error was noticed in the sequence of GSTP1.  As 
this incorrect nucleotide caused an amino acid substitution from proline at amino 
acid position 2 (P2) to arginine and is a change that might affect protein folding and 
therefore enzyme function, this sequence error was corrected using site directed 
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mutagenesis prior to transfection (Appendix A and B).  The GSTM1 sequence was 
consistent with the reference sequence from the Genbank database 
(NM_000561.3).  
Despite a total of four individual attempts, 22Rv1 cells stably expressing 
GSTP1 could not be selected. In each experiment, a G418-resistant population 
containing the empty vector remained after the two week selection period 
suggesting that expression of GSTP1 did not allow continued growth of the 22Rv1 
cells.  Four individual heterogenous populations of stable, G418-resistant 22Rv1 
cells were however obtained from the cells transfected with the GSTM1 expression 
vector and expression of the GSTM1 protein was confirmed using Western analysis 
(Figure 3.5).  Robust expression was seen in each of the four replicate populations 
as evidenced by the strongly immunoreactive bands in the appropriate lysate lanes 
when compared with the parental 22Rv1 cells and 22Rv1 cells transfected with the 
empty vector (22Rv1-VO).  In all cases the protein was migrating at 27 kDa 
consistent with monomeric GSTM1 protein.  
 To determine if GSTM1 protein exogenously over-expressed by the 22Rv1 
cells was loaded into microvesicles, microvesicles were prepared from the medium 
and analysed using Western analysis. GSTM1 was consistently detected, albeit at 
low levels, in the microvesicle preparations derived from the GSTM1-transfected 
22Rv1 cells at the monomeric size of 27 kDa, with comparison to both the parental 
22Rv1 and 22Rv1-VO cells. There was no band present at 75 kDa that had 
previously been seen in DU145 and LNCaP derived exosomes. TSG101 was again 
used as an exosome marker and loading control that showed even loading of the 
microvesicle preparations at 48 kDa (Figure 3.6). Microvesicles were also imaged 
with TEM (Figure 3.7) to observe any morphological changes that may have 
occurred after transfection and as a consequence of exogenous GSTM1 expression. 
The GSTM1 over-expressing cells mostly shed large exosomes which is different to 
the 22Rv1 parental cells that shed a majority of prostasomes. This change in 
vesicles may be due to G418 selection pressure. 
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Figure 3.5: Western blot showing over-expression of GSTM1 in transfected 
22Rv1 whole cell lysates. The protein of interest, GSTM1 was present at the monomeric 
size of 27 kDa in all transfected 22Rv1 replicates (22Rv1-M1). It was not present in the 
vector only 22Rv1 (22Rv1-VO) cells or the 22Rv1-Parental cells as expected. GSTM1 was 
present as a monomeric protein. GAPDH was used as a loading control. 
 
  
 
 
 
 
 
 
Figure 3.6: Western blot showing the packaging of GSTM1 into shed 
exosomes derived from GSTM1 transfected 22Rv1 cells.GSTM1 was detected in 
all exosomes preparations from 22Rv1-M1 cells and not expressed in 22Rv1-P or 22Rv1-VO 
cells as expected. GSTM1 was present only as a monomeric protein. TSG101 was used as 
an exosome marker and loading control and indicated even loading at 48 kDa. 
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Figure 3.7: Transmission Electron Microscopy image of exosomes isolated 
from GSTM1 over-expressing 22Rv1 conditioned medium. Conditioned medium 
was collected from 22Rv1-M1 cells after 24 h of incubation and differentially centrifuged to 
remove cellular debris. The exosome preparations were then resuspended in DPBS and 
analysed with TEM by negatively staining with 1% uranyl acetate. The exosomes appeared 
spherical and cup shaped at an approximate size of 30-200 nm. The image is at 15,000X 
magnification and the microscope was operating at 80 kV. 
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Table 3.3: Quantitation of microvesicles (exosomes and prostasomes) in one TEM grid from GSTM1 over-expressing 22Rv1 cells and 
22Rv1 parental cells (from Table 3.1) based on diameter. 
 
 
Table 3.3 compares the different vesicles shed from the 22Rv1 parental and the GSTM1 over-expressing cell line. The engineered cells shed 
more large exosomes than the parental cells and conversely shed a smaller amount of prostasomes than the parental cells. 
 
Cell line Total Number of 
Small 
Exosomes   
Average 
diameter 
and range 
% of 
total 
Number of 
Large 
Exosomes 
Average 
diameter and 
range 
% of 
total 
Number of 
Prostasomes 
Average 
diameter and 
range 
% of 
total 
22Rv1 47 17 40 nm 
20 - 80 nm 
36% 18 120 nm 
80 – 120 nm 
38% 12 150 nm 
120 – 250 nm 
25% 
22Rv1-M1 42 6 30 nm 
20 - 80 nm 
14% 33 100 nm 
80 – 120 nm 
79% 3 200 nm 
120 – 250 nm 
7% 
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3.4 DISCUSSION 
 
GST enzymes are involved in detoxification and if we are able to identify GST 
positive enzymes in the blood of patients with prostate cancer and in the exosomes, 
we may be able to predict patients who may not respond favourably to treatment 
with chemotherapeutics. This would significantly decrease the amount of money 
spent on treatment and more importantly, provide disease specific patient care with 
fewer side effects. The detection of four particular cytosolic GST enzymes - GSTP1, 
GSTT1, GSTM1 and GSTM3 - were studied where GSTP1 and GSTT1 have 
previously been linked to prostate cancer however there is little information 
regarding GSTM1 and GSTM3. 
A variety of PCa cells were used throughout this study, representing the change 
from androgen dependent to androgen independent prostate cancer. 22Rv1 cells 
represented androgen responsive cancer, LNCaP cells represented androgen 
dependent cancer and DU145 and PC3 cells represented androgen independent 
cancer [Chlenski, 2001; Marchiani, 2010]. The GST profiles were conducted in each 
of these cell lines to see if certain GSTs were expressed in different cancer stages. 
GSTP1 was present at the monomeric size in DU145 and PC3 cell lysates and 
faintly in LNCaP and 22Rv1 lysates. This indicates that GSTP1 may only be 
expressed in androgen independent cases, such as during castrate resistant 
prostate cancer. GSTT1 was present as both a monomer and dimer in all cell 
lysates showing that it is present throughout the progression of prostate cancer. 
GSTM1 was only present in LNCaP lysates as a putative dimer and not in any other 
lysates suggesting that it may only be present in androgen dependent prostate 
cancer. Also the transition from a homodimer, to a dimer to then a monomer is 
protein concentration dependent. If the first transition is bimolecular, subunit 
dissociation occurs and produces a monomer however if the second transition is 
protein concentration dependent, then the subunits dissociate after the formation of 
a dimer, requiring an extra dissociation step. The molecular origin for the ability of 
dissociated mu class subunits to exist as stable structures may involve interactions 
that are specific for GSTM1 like the presence of the mu loop [Hornby, 2000]. The 
extra step required for dissociation of the dimer may explain why GSTM1 was only 
consistently present as a dimer. The specificity of the GSTM1 antibody could also 
be tested by knocking down GSTM1 and seeing if the bands remained. Like GSTT1, 
GSTM3 was present in all of the lysates as a monomeric protein throughout the 
progression of prostate cancer. It was unusual that GSTM3 didn’t follow the same 
lysate expression profile as GSTM1 however this may be due to the functionality of 
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the enzymes themselves.  Differences in the gene expression levels and protein 
levels may indicate different levels of regulation for these GST enzymes.  For 
example, the GSTM1 gene was expressed in DU145, PC3 and LNCaP cells yet 
protein was only detected in the sample from the LNCaP line.  This may indicate a 
further mechanism for regulation of this enzyme occurring after transcription in the 
DU145 and PC3 cells or it might show that the GSTM1 protein, if made, is rapidly 
degraded by the cell. Understanding all mechanisms involved in GST regulation is 
important. To further understand why the extra bands were seen, GSTM1 could be 
knocked down using siRNA to see if the band is no longer present which would also 
validate the results. 
Recent studies of exosomes from various cancer cell lines recommended 
isolating these small vesicles by several different methods including 
ultracentrifugation, sucrose or OptiPrep™ density-based separation and 
immunoaffinity capture with anti-EpCAM-coated magnetic beads [Tauro, 2012]. 
These methods all have their own limitations as density-based methods exclude 
vesicles based on size and buoyancy and immunoaffinity methods require 
microvesicles to have EpCAM presented on the membrane. Ultracentrifugation was 
used in this study as it captures a more representative pool of microvesicles. By 
using ultracentrifugation, microvesicle preparations were likely to include both 
exosomes and prostasomes with an overlap in sizes and differences in the 
membrane composition as exosomes have a simple lipid bilayer and prostasomes 
have multilayers rich in cholesterol and sphingomyelin. Prostasomes can be 
differentiated from exosomes by size and also by analysing cholesterol and 
sphingomyelin content. Prostasome multilayers are unable to be visualised with 
TEM however they can be identified by their size as they are generally much larger 
than exosomes [Chiasserini, 2015]. 
During this study, the prostasomes and exosomes were not differentiated as 
exosome preparations yielded small and large exosomes and prostasomes so this 
collective group of vesicles were referred to as microvesicles. The microvesicles 
were directly loaded and probed with the appropriate GST antibodies. GSTP1 was 
present in the DU145 and PC3 microvesicles as a monomer, identical to the protein 
lysate profile. GSTT1 did not appear to be packaged into any of the shed 
microvesicles which was unusual as it was present in all of the lysates. GSTM1 was 
present in LNCaP microvesicles as a monomer and surprisingly, in DU145 
microvesicles. This suggests that GSTM1 may in fact be preferentially loaded into 
DU145 microvesicles. Similarly to the GSTM1 profile, GSTM3 was also present only 
in DU145 and LNCaP microvesicles as a monomer. Since it was present in all of the 
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prostate cancer lysates and only in the DU145 and LNCaP microvesicles, this 
shows that similar to GSTM1, GSTM3 is also preferentially loaded into particular 
microvesicles. Given that GST enzyme function relies on formation of a stable 
dimer, the observation that GSTM1 is present as a monomer in microvesicles might 
suggest that the enzyme is in an inactive state.  Furthermore, although the identity 
of the 75 kDa band seen on Western blot analysis using protein lysates from LNCaP 
and DU145 microvesicles is unknown, its immunoreactivity with the GSTM1-specific 
antibody may have identified this as a complex of GSTM1 protein and an as yet 
unidentified binding partner.  This band was present in sample that had been both 
denatured and reduced which would suggest a strong covalent interaction if this is 
the case. An immunoprecipitation procedure coupled with mass spectrometry 
analysis of this complex might clarify this. 
To determine the best candidate for the over-expression studies, the protein 
and microvesicle profiles were studied. It was apparent that over-expressing GSTP1 
and GSTM1 in 22Rv1 cells was the most appropriate choice. This was due to the 
fact that neither of these enzymes were present in the protein lysates or 
microvesicles. GSTT1 and GSTM3 were not chosen as GSTT1 was not present in 
the microvesicles and the biological activity of GSTM3 is very similar to the activity 
of GSTM1. It was important to see if over-expressing GSTs could potentially lead to 
the GSTs being loaded into the microvesicles. After performing site-directed 
mutagenesis on GSTP1 to correct the incorrect base, it was transfected into 22Rv1 
cells with Lipofectamine. This was attempted four times and each time the 22Rv1-
VO cells remained while the transfected 22Rv1-P1 cells died. This suggests that 
since GSTP1 was unable to be expressed in 22Rv1 cells, it could be tumour 
suppressive or downregulated by DNA CpG methylation, however further research 
would need to be performed to confirm this [Gray, 2012]. There is much controversy 
about its expression in relation to prostate cancer where the progression of cancer is 
related to silencing GSTP1 by methylation and conversely, GSTP1 over-expression 
being linked to tumour progression. A study by Lee et al. showed that GSTP1 was 
downregulated in prostate tumour samples compared to the normal tissue [Lee, 
1994]. The results from this study show that GSTP1 probably contributes to prostate 
cancer progression through the production of GST intermediates which cause DNA 
damage. GSTP1 is most likely cell line dependent as it was highly expressed in 
DU145 and PC3 mRNA and protein as well as LNCaP mRNA. GSTP1 was only 
faintly present in 22Rv1 mRNA and not at all in protein lysates suggesting that these 
cells don’t require GSTP1. GSTM1 was able to be stably expressed in 22Rv1 cells. 
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This would suggest that the targets of these two GST enzymes were different in the 
22Rv1 cells. 
Future studies could include screening patient samples to see if patient derived 
exosomes contain GST enzymes. Blood samples and seminal fluid appear to be the 
most appropriate sample types. Seminal fluid is a more appropriate fluid to examine 
as about 30% of seminal fluid comes from the prostate and naturally contain more 
prostasomes [Tavoosidana, 2011; Aalberts, 2013]. GSTP1 content in exosomes in 
particular may be a good candidate for monitoring prostate cancer progression as 
methylated GSTP1 is currently being used in some prognostic studies. Early 
disease states may be detected using seminal fluid as the duct structures would still 
be intact and once tissue architecture has become disrupted by the tumour itself, 
there would most likely be more exosomes released into the bloodstream.  
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Chapter 4: GSTM1 over-expression affects the 
behaviour of Prostate Cancer and associated stromal 
cells 
 
4.1 INTRODUCTION 
Glutathione-S-transferase enzymes are a superfamily of enzymes that, through 
their ability to catalyse the nucleophilic addition of the glutathione tripeptide (GSH - 
-Glu-Cys-Gly) to various reactive electrophiles, play a key role in cellular 
detoxification and protection from carcinogens, reactive oxygen species and 
chemotherapeutic agents.  The expression of several GST enzymes is commonly 
dysregulated in cancers including prostate cancer through a variety of different 
cellular mechanisms including gene amplification, transcriptional activation, protein 
stabilisation and genetic polymorphisms [Matthias, 1998; Di Pietro, 2010].  
Dysregulation can be due to reduced or loss of expression or conversely, over-
expression and both have been linked to cancer progression. Reduced expression 
of GST mu family enzymes is predicted to contribute to cancer initiation through 
uncontrolled and increased oxidative stress and resultant DNA damage in the 
prostate gland [Frohlich, 2008]. A meta-analysis combining data from 29 different 
studies (4564 cases and 5464 controls) showed that individuals with a GSTM1 null 
genotype have an increased risk of developing prostate cancer [Mo, 2009]. Over-
expression of GST enzymes however, has been linked by several studies to 
resistance to chemotherapeutic drugs.  For example, GSTP1 is often more highly 
expressed in breast cancer cells of patients with poor clinical outcome and low 
overall survival [Miyake, 2012; Saxena, 2012]. GSTP1 can detoxify 
chemotherapeutic drugs inside neoplastic cells, making these cells resistant to 
chemotherapy [Jardim, 2012]. In lung cancer cells, GSTP1 expression is 
consistently up-regulated compared to normal lung tissue and appears to be directly 
related to the development of chemotherapeutic resistance [Mattern, 2002]. 
Alternatively, over-expression and increased activity of other GST enzymes has 
been linked to the production of genotoxic intermediates, as is the case for GSTT1 
which is often highly expressed in the prostate where it correlates with PCa risk 
[Rebbeck, 1999]. 
Although many different studies have linked various GSTM1 gene 
polymorphisms to prostate cancer risk [Mo, 2009; reviewed in Di Pietro, 2010], only 
a few have explored the expression and function of the protein itself in prostate 
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cancer cells. High expression levels of GSTM1 have previously been reported in 
several drug-resistant tumour cell lines and malignant drug-resistant melanoma 
metastases [Peters, 1994]. In transitional cell cancer (TCC) of the human bladder, 
GSTM1 was significantly increased (average 2.8-fold) in TCC specimens compared 
to levels in normal adjacent mucosa [Berendsen, 1997]. 
In the research described in Chapter 3, expression of GSTM1 was identified by 
RT-PCR in the DU145, PC3 and LNCaP prostate cancer cell lines. Dimeric GSTM1 
protein was detected by Western analysis in total protein lysates from LNCaP cells 
but was undetectable in the DU145 and PC3 samples. Interestingly, GSTM1 
proteins were detected in exosome preparations from both LNCaP and DU145 
suggesting that in the DU145 cells, GSTM1 may be preferentially loaded into 
exosomes for an extracellular function. In both LNCaP and DU145 exosomes, 
GSTM1 is present in the monomeric form, with no dimeric protein identified, and a 
higher molecular weight band at approximately 75 kDa may identify an exosome-
related protein complex containing GSTM1.  
Little has been reported about the potential role for GSTM1 in prostate cancer 
and the initial aim of the research described in this Chapter was to determine the 
effects of over-expression of GSTM1 on the proliferation of GSTM1-null prostate 
cancer cells.  Then, because GSTs are able to protect tumour cells from the 
cytotoxicity of anti-cancer drugs, prostate cancer cell lines were treated with 
docetaxel to determine if over-expression of GSTM1 increased resistance to this 
chemotherapeutic drug. Loading of GSTM1 into exosomes was explored by 
comparing the GSTM1 levels in exosomes prepared from over-expressing, vector 
only and parental cells. Finally, exosomes loaded with GSTM1 were added to the 
medium of prostate cancer cells and stromal prostatic cells (WPMY-1 cell line) to 
determine whether GSTM1 loaded into exosomes could protect these cells from 
treatment with docetaxel, a commonly used anti-mitotic chemotherapeutic agent 
[Eisenberger, 2012].  
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4.2  MATERIALS AND METHODS 
 The common materials and methods relevant to this chapter have been outlined 
in Chapter 2. 
 
4.2.1 STATISTICAL TESTS 
Statistical analyses comparing results from three independent experiments 
were completed using a two-tailed Student's t-test and either GraphPad Prism (La 
Jolla, CA, USA) or Microsoft Excel Software. Data is represented as mean ± 
standard error of the mean (SEM) and statistical significance was set at p≤ 0.05. 
 
4.3 RESULTS 
 
4.3.1 RESPONSE OF PROSTATE CANCER CELL LINES TO DOCETAXEL 
DU145 and 22Rv1 have been reported to show some resistance to 
docetaxel and resistant populations have been established from both lines by others 
[Corcoran, 2012]. To confirm that the DU145 and 22Rv1 cells available in our 
laboratory respond to docetaxel as reported, cells were treated for 24 h and 72 h 
with docetaxel at a range of increasing concentrations of docetaxel from 0 nM 
(vehicle only – 0.01% DMSO) to 40 nM. This range of doses was chosen according 
to current literature [Hao, 2010; Toner, 2013]. Cell viability was measured using a 
colorimetric MTS assay (Promega) where the MTS tetrazolium compound (Owen’s 
reagent) is reduced by cells into a soluble coloured formazan product which is then 
measured by determining the absorbance at 490nm. Production of the coloured 
formazan product requires NADPH or NADH produced by dehydrogenase enzymes 
in metabolically active cells and is therefore proportional to the number of viable 
cells. Viability of DU145 cells started to decrease when the cells had been treated 
for 24 h with a docetaxel concentration of 5 nM and a further reduction in viability 
was seen with increasing docetaxel concentration (Figure 4.1).  Cells treated for 72 
h also responded to increased docetaxel concentration with less viability seen, 
reaching the IC50 at approximately 12 nM.  The 22Rv1 cell line population seemed to 
be more resistant to docetaxel at all concentrations after 24 h but the cells did begin 
to respond on further treatment for 72 h.  The IC50 for 22Rv1 cells was not reached 
in this experiment (even with a docetaxel concentration of 40 nM). 
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Figure 4.1: Dose-response curves of Docetaxel resistant prostate cancer cell 
lines after treatment with Docetaxel for 24 and 72 hours. Cells were treated with a 
range of Docetaxel (Vehicle, 0.1, 1, 5, 10, 20 and 40 nM) for 24 hours. IC50 represented by 
dotted lines. Error bars = SEM. n = 3 for each cell line at each time-point. 
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To confirm that the docetaxel treatment regime was appropriate to determine 
resistance, the sensitive cell lines LNCaP and PC3 were also treated with docetaxel 
under the same conditions (Figure 4.2).  Treatment with 10 nM of docetaxel for 24 h 
was sufficient to reach the IC50of the LNCaP cells at 72 h of treatment approximately 
2 nM was enough confirming that LNCaP is a docetaxel sensitive cell line and that 
the docetaxel treatment was working. PC3 cells appeared less sensitive to 
docetaxel than LNCaP, and the IC50 was not achieved with any concentration by 24 
h.  At 72 h however, 50% of the cells were no longer viable when treated with 5 nM 
docetaxel. 
 
 
Figure 4.2: Dose-response curves of Docetaxel sensitive prostate cancer cell 
lines after treatment with Docetaxel for 24 and 72 hours. Cell lines were treated 
with a range of Docetaxel (Vehicle, 0.1, 1, 5, 10, 20 (LNCaP) and 40 nM (PC3)) for 24 and 
72 hours. IC50 represented by dotted lines. Error bars = SEM. n = 3 for each cell line at each 
time-point. 
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4.3.2 PROLIFERATION OF GSTM1OVER-EXPRESSING 22Rv1 CELLS 
 In Chapter 3, an experiment designed to test whether exogenous over-
expression of GSTM1 in GSTM1-naïve 22Rv1 cells would result in loading of 
GSTM1 into exosomes released by these cells was described. The 22Rv1 cell line 
was used as a model for this experiment as the cells produce no detectable GSTP1 
or GSTM1 and only little GSTM3 and GSTT1. To our knowledge the contribution of 
GSTM1 enzyme activity to docetaxel resistance has not been reported in the 
scientific literature and the availability of the 22Rv1-M1 lines allowed testing of this. 
Firstly, a proliferation assay was performed to compare growth of the parental 
22Rv1-P, vector only 22Rv1-VO and the 22Rv1-M1 expressing populations (for 
22Rv1-M1 cells, data from 4 individual heterogenous polyclonal populations were 
combined). Proliferation was measured at three different time points after seeding - 
at 4 h to normalise the attached cell number of each population after seeding and 
then at 24 h and 72 h to compare proliferation of the different populations (Figure 
4.3). Parental cells appeared to proliferate the fastest and the significant reduction in 
proliferation seen in the 22Rv1-VO cells may be due to the continual selective 
pressure of culturing in G418 containing medium.  In comparison to the 22Rv1-VO 
cells, the 22Rv1-M1 cells also showed a significant decrease in proliferation 
suggesting that over-expression of GSTM1 puts further growth pressure on these 
cells.  
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Figure 4.3: Proliferation of 22Rv1-M1 cell line compared with 22Rv1-VO and 
parental 22Rv1 (22Rv1-P) cells. There was a significant decrease in proliferation of the 
GSTM1 over-expressing cell lines compared to the vector control at 72 h. n = 3. Error bars = 
SEM.*** p≤ 0.001, **** p≤ 0.0001 according to Student’s t test. 
 
4.3.3 PROLIFERATION OF GSTM1 OVER-EXPRESSING 22Rv1 CELLS 
TREATED WITH DOCETAXEL 
Although 22Rv1 does appear to demonstrate some resistance to docetaxel, a 
proliferation assay was used to determine whether over-expression of GSTM1 might 
increase the resistance of these cells when challenged with docetaxel.  Parental 
22Rv1-P, vector only 22Rv1-VO and the 22Rv1-M1 populations were treated with 
20 nM docetaxel for 72 h and viability measured using the MTS assay. Consistent 
with the proliferation assay described above, treatment with 20 nM docetaxel 
correlated with a reduction in cell viability for the cells that were transfected with the 
empty vector when compared with the parental 22Rv1 cells (Figure 4.4).  
Expression of GSTM1 however resulted in a significant increase in viability of cells 
treated under the same conditions suggesting that increased expression of GSTM1 
provides a mechanism for detoxification of docetaxel. Given the decrease in 
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proliferation seen when these cells are grown without docetaxel (Figure 4.3) this 
increase in viability may be even greater than measured in this experiment. 
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Figure 4.4: Proliferation of 22Rv1-P and 22Rv1-M1 cells compared with 22Rv1-
VO after treating with 20 nM Docetaxel for 72 h. There was a significant increase in 
cell proliferation of 22Rv1-M1 cells compared to the vector control suggesting increased 
resistance to docetaxel. n = 3. Error bars = SEM. **** p≤ 0.0001 according to Student’s t test. 
 
4.3.4EFFECT OF EXOSOME ADDITION DURING TREATMENT OF DOCETAXEL-
RESISTANT CELLS WITH DOCETAXEL 
 Published experimental data suggest that exosomes produced by cancer 
cells can influence the behaviour of cells within the tumour microenvironment and 
even possibly help to determine the pre-metastatic niche [Jung, 2009]. To determine 
whether addition of exosomes would also increase the proliferation of cell lines that 
show some resistance to docetaxel, exosomes prepared from 22Rv1-VO cells and 
22Rv1-M1 cells were added to the medium for treatment of DU145 and parental 
22Rv1 cells, again in the presence or absence of docetaxel (Figures 4.5 and 4.6). 
Cells were incubated for up to 72 h and proliferation measured at both 24 h and  
72 h. As seen in Figure 4.5, DU145 continued to proliferate in the presence of 
docetaxel which was expected for a resistant cell line, although why this proliferation 
was approximately 1.5 fold more than the vehicle-treated cells is not clear.  Addition 
of 100 μg/mL 22Rv1-VO and 22Rv1-M1 exosomes resulted in an increase in cell 
proliferation in normal cell culture and in the presence of 20 nM docetaxel.  A further 
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increase in proliferation was seen when twice as many exosomes (200 μg/mL) were 
added. 
 Exosomes were also added to the medium of 22Rv1 parental cells (Figure 
4.6).  An increase in proliferation was again seen in the 22Rv1 cells treated with 100 
μg/mL of the 22Rv1-VO exosomes but this proliferation response was lost when this 
was increased to 200 μg/mL suggesting that too many exosomes may be inhibitory 
to cell growth.  This may be the case if the exosomes produced by these cells are 
being used to remove unwanted cellular contents.  Interestingly however, treatment 
with100 μg/mL 22Rv1-M1 exosomes correlated with an increase in proliferation by 
approximately 3 fold and this increased to almost 9 fold when 200 μg/mL exosomes 
were added for 72 h.  This would suggest that loading of GSTM1 into exosomes 
may provide more resistance to docetaxel even in the parental cells. 
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Figure 4.5: Proliferation of DU145 cells in the absence or presence of docetaxel and exosomes. (A) Addition of 100 µg/mL exosomes. (B) 
Addition of 200 µg/mL exosomes. Cells were untreated (Vehicle – DMSO), treated with 20 nM docetaxel or treated with docetaxel and exosomes. n = 3. Error 
bars = SEM. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001 according to Student’s t test. 
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Figure 4.6: Proliferation of 22Rv1 cells in the absence or presence of docetaxel and exosomes. (A) Addition of 100 µg/mL exosomes. (B) 
Addition of 200 µg/mL exosomes. Cells were untreated (Vehicle – DMSO), treated with 20 nM docetaxel or treated with docetaxel and exosomes. n = 3. Error 
bars = SEM.*** p≤ 0.001, **** p≤ 0.0001 according to Student’s t test. 
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4.3.5EFFECT OF EXOSOME ADDITION DURING TREATMENT OF DOCETAXEL-
SENSITIVE CELLS WITH DOCETAXEL 
Similar to 4.3.4, the effect of GSTM1 loaded exosomes shed by 22Rv1-M1 
cells was studied to observe whether or not the exosomes provide protection from 
chemotherapeutic agents. 100 μg/mL or 200 μg/mL solution of exosomes in growth 
medium was added to cultures of the docetaxel sensitive cell lines PC3 and LNCaP, 
with and without 20 nM docetaxel.  Cells were incubated for up to 72 h and 
proliferation measured at 24 and 72 h.  The addition of both 22Rv1-M1 and 22Rv1-
VO exosomes to PC3 cells increased cell proliferation in both the absence and 
presence of docetaxel. This was particularly interesting as the IC50 for PC3 cells at 
72 h was 5 nM. The results, as seen in Figure 4.7, showed that even the addition of 
exosomes themselves increased proliferation in cultures without docetaxel. 
Interestingly, the proliferation also increased when cultured with docetaxel as well 
and this shows that exosomes containing GSTM1 and exosomes that don’t contain 
GSTM1 also provide tumour protective properties. Similar results are seen when 
both concentrations of exosomes are used. 
The proliferation of LNCaP cells increased dramatically when cultured with 
docetaxel and exosomes. This was particularly interesting as the IC50 of LNCaP 
cells was 2 nM at 72 h and this proliferation increase shows that exosomes with the 
aid of GSTM1 play a definite protective role in LNCaP cells. Treatment with 100 
μg/mL 22Rv1-VO exosomes resulted in a significant increase in proliferation in the 
docetaxel untreated cells (from 1.8 fold to almost 5 fold). An increase in proliferation 
was also seen in the cells treated with 22Rv1-M1 exosomes although this was less 
than the VO cells (1.8 fold to 3.3 fold), perhaps consistent with the proliferation data 
that suggests over-expression of GSTM1 has a slight negative effect on the cells.  
Cells co-treated with both exosomes and docetaxel also had significantly higher 
proliferation than cells treated with docetaxel alone and in this experiment there was 
no significant difference in the proliferation of cells treated with exosomes from 
either the 22Rv1-VO cells or the 22Rv1-M1 cells. Similar results are also seen when 
200 µg/mL exosomes are used. 
 
.  
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Figure 4.7: Proliferation of PC3 cells in the absence or presence of docetaxel and exosomes. (A) Addition of 100 µg/mL exosomes. (B) 
Addition of 200 µg/mL exosomes. Cells were untreated (Vehicle – DMSO), treated with 20 nM docetaxel or treated with docetaxel and exosomes. n = 3. Error 
bars = SEM. * p≤ 0.05, ** p≤ 0.01, **** p≤ 0.0001 according to Student’s t test.  
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Figure 4.8: Proliferation of LNCaP cells in the absence or presence of docetaxel and exosomes. (A) Addition of 100 µg/mL exosomes. (B) 
Addition of 200 µg/mL exosomes. Cells were untreated (Vehicle – DMSO), treated with 20 nM docetaxel or treated with docetaxel and exosomes. n = 3. Error 
bars = SEM.**** p≤ 0.0001 according to Student’s t test. 
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4.3.6EFFECT OF EXOSOME ADDITION DURING TREATMENT OF STROMAL 
CELLS (WPMY-1) WITH DOCETAXEL 
To determine whether exosomes produced by cancer cells can influence the 
behaviour of stromal cells found within the tumour microenvironment, cells of the 
stromal prostatic fibroblast cell line WPMY-1 were then treated with medium 
containing 100 or 200 µg/mL exosomes from 22Rv1-VO and 22Rv1-M1 cells in the 
presence or absence of docetaxel where proliferation was measured at 4, 24 and 72 
hours (Figure 4.9). Again, the effect of adding concentrations of 100 μg/mL or 200 
μg/mL of exosomes to the proliferation of WPMY-1 cells was compared at 24 h and 
72 h. In the vehicle only treated culture, WPMY-1 cells proliferated 1.8 fold over the 
72 h time period of this experiment. As expected, docetaxel treatment caused a 
decrease in proliferation of WPMY-1 cells with only a third of the untreated cell 
number (0.6 fold) remaining at 72 h. Addition of 100 μg/mL exosomes, either 22Rv1-
VO or 22Rv1-M1, had little effect on the proliferation of these cells in the absence of 
docetaxel suggesting that the growth advantage seen for the prostate cancer cells 
might be cell context dependent.  Interestingly, addition of exosomes from either 
22Rv1-VO or 22Rv1-M1 cells rescued the WPMY-1 cells from docetaxel treatment, 
restoring proliferation to that of the vehicle treated cells suggesting that these 
exosomes both carry proteins that off-set the negative growth effect of the 
docetaxel.  Little benefit was seen from the addition of twice as many exosomes 
when the cells were in normal cell culture but a significant increase in proliferation 
was seen when 200 μg/mL exosomes were added to the WPMY-1 cells treated with 
docetaxel and this may be related to the increased levels of GSTM1 in these 
exosomes.  
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Figure 4.9: Proliferation of WPMY-1 cells in the absence or presence of docetaxel and exosomes. (A) Addition of 100 µg/mL exosomes. (B) 
Addition of 200 µg/mL exosomes. Cells were untreated (Vehicle – DMSO), treated with 20 nM docetaxel or treated with docetaxel and exosomes. n = 3. Error 
bars = SEM. **** p≤ 0.0001 according to Student’s t test.
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4.4 DISCUSSION 
  
There are various studies suggesting that the expression of GST enzymes can 
either be tumour promoting or suppressive. This study in particular showed that 
exosomes carrying GSTM1 was tumour promoting. The 22Rv1-M1 cells significantly 
decreased in proliferation when compared to both the 22Rv1-P and 22Rv1-VO cells 
however in the presence of 20 nM docetaxel, cell viability of the 22Rv1-M1 cells 
increased compared to the parental and vector only cells.  
To determine whether exosomes carrying GST enzymes might confer 
resistance to chemotherapeutic agents, cells were treated with a combination of 
exosomes and docetaxel.  Docetaxel was chosen for this study because it is the 
most commonly used anti-mitotic agent for treatment of advanced and castrate 
resistant prostate cancer. Published data suggests that GSTP1 is able to detoxify 
docetaxel [Arai, 2008] however, to our knowledge, the ability of GSTM1 to detoxify 
docetaxel, or other chemotherapeutic drugs, has not been determined.  A panel of 
prostate cancer cell lines that were variably resistant (DU145 and 22Rv1) and 
sensitive (PC3 and LNCaP) to docetaxel allowed the testing of the hypothesis that 
GSTM1 could be carried in exosomes and this might provide increased resistance to 
docetaxel treatment. In the first part of the study reported in this Chapter, docetaxel-
sensitive 22Rv1 cells were transfected with an expression construct containing the 
complete coding sequence of GSTM1under control of the constitutive CMV-IE 
promoter. Although the proliferation of 22Rv1-M1 cells was lower than that of the 
parental and vector only cells, proliferation was higher in 22Rv1-M1 cells than the 
22Rv1-VO cells when these were treated with docetaxel for 72 h. This suggests that 
although GSTM1 expression in 22Rv1 may be detrimental during conditions of 
normal growth, it does provide a growth advantage when cells are challenged with 
docetaxel. This result also supported the use of docetaxel in further experiments. 
Exosomes are thought to be an important means of cell to cell communication 
between cells within the immediate tumour microenvironment or at more distant 
sites in the body.  To determine whether exosomes might have local effects on other 
cells including other tumour cells and stromal cells, exosome preparations were 
added to various cell populations and the effect on cell proliferation determined.  In 
the first experiments the interaction of 22Rv1-M1 exosomes with cancer cells 
including docetaxel resistant DU145 and 22Rv1 parental cells and docetaxel 
sensitive LNCaP and PC3 cells, was determined. In keeping with similar studies of 
gastric and breast cancers [Qu, 2009; Koga, 2005], addition of exosomes to cell 
culture medium stimulated proliferation of cells, regardless of loading with GSTM1, 
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which would suggest that exosomes from prostate cancer cells carry growth 
promoting macromolecules. A clear growth benefit was seen when exosomes 
carrying GSTM1 were added to cells treated with docetaxel supporting the 
hypothesis that GSTM1 enzymes can be carried in exosomes to other cells and 
thereby assist in cancer cell resistance to docetaxel.  It is perhaps not surprising that 
GSTM1 exosomes showed a more beneficial effect on cells that were sensitive to 
Docetaxel than those that were inherently more resistant. Reconstruction of 
autocrine stimulation by treating 22Rv1 cells with exosomes shed from 22Rv1 cells 
also resulted in increased proliferation of cells. Parental 22Rv1 cells appeared to be 
much more responsive to what may be a self-perpetuating signal. 
Exosomes released from tumour cells may also influence growth and behaviour 
of stromal cells within the tumour microenvironment. In a study regarding breast 
cancer, it was shown that prostatic stromal fibroblasts promoted metastasis in breast 
cancer. Metastasis promotion was influenced by TGF-β1 secreted by fibroblasts in 
vitro [Stuelten, 2010]. Other fibroblasts such as cancer associated fibroblasts are 
able to induce chemotherapy resistance during breast cancer treatment [Martinez-
Outschoorn, 2011]. This is due to the collagen type I secreted by the CAFs as it 
decreases chemotherapeutic drug uptake in tumours and plays a significant role in 
regulating tumour sensitivity to a variety of chemotherapies [Loeffler, 2006].  In the 
experiment reported in this Chapter, when WPMY-1 cells were treated with 22Rv1-
M1 exosomes an increase in proliferation was also seen, even in the presence of 
docetaxel.   
When considered as a whole, these experiments show that exosomes can 
stimulate proliferative responses in a paracrine and autocrine manner and that GST 
enzymes loaded as cargo into exosomes may contribute to resistance to docetaxel, 
an important prostate cancer chemotherapeutic. Novel anti-cancer strategies may 
therefore include those that can block exosome GST loading, inhibit GST activity or 
even remove exosomes from circulation.  
The results presented in this chapter have shown that GSTM1 over-expression 
in prostate cancer cells can be loaded into shed exosomes. A recent study has 
shown the benefits of treating Parkinson’s disease with exosomes containing 
specific Parkinson’s disease treatments [Haney, 2015] and it may be possible to 
express anti-cancer proteins and peptides in cells that then package these into 
exosomes for transfer to tumour cells [Kim, 2015]. Exosome packaging could 
potentially be a new and valuable option for delivery of anti-tumour therapies but this 
can only be realised with further research.  
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Chapter 5: General Discussion 
 
GST expression has been a widely researched and often controversial topic 
in cancer. Studies suggest that the GSTP1 protein promotes tumour growth and 
progression [He, 2011] and others believe that it may be tumour suppressive [Gray, 
2012]. Methylated GSTP1 has been suggested as a potential prognostic marker for 
prostate cancer and has been the focus of many clinical trials [Mahon, 2014]. 
Despite several attempts throughout the study, it did not seem possible to transfect 
22Rv1 cells with an expression construct to exogenously over-express GSTP1.  
This would suggest that in this particular cell line, GSTP1 may function as a tumour 
suppressor however might be cell context dependent and should be tested in other 
cell lines using an inducible expression system.  
 The functional and clinical effects in prostate cancer of many of the other 
classes, and particularly GSTT1, GSTM1 and GSTM3, have not yet been studied in 
detail because to date the focus has been the relevance of polymorphisms found in 
several different populations [Matthias, 1998; Di Pietro, 2010; Mo, 2009; reviewed in 
Di Pietro, 2010]. The data presented here suggests that GSTM1 may contribute to 
resistance to docetaxel in sensitive cells and that GSTM1 can be loaded into 
exosomes and delivered to cells to increase proliferation and docetaxel resistance, 
two key findings that add to the knowledge of both GSTM1 enzyme and exosome 
functions. This study examining the effect that GSTs and exosomes have on the 
proliferation of prostate cancer cells is the first functional study of GSTM1’s cellular 
effect. To the best of my knowledge, there are no published studies about GST 
loaded exosomes affecting cancer progression in both untreated and treated cells.  
Protein profiles of the various GSTs were conducted to see if the inactive 
monomeric or active dimeric form of GSTs were present in a range of prostate 
cancer cells and their shed exosomes. Proteomic profiling has shown that proteins 
packaged into shed exosomes are different from the proteins present in the parent 
cells [Théry, 2006; Duijvesz, 2013; Hosseini-Beheshti, 2012]. GSTT1 was present in 
all of the prostate cancer lysates as a monomer but not in any of the shed exosomes 
as either a monomer or dimer. GSTM1 was present in only the LNCaP lysates as a 
dimer and packaged as a monomer into shed exosomes as well as being packaged 
into DU145 exosomes, both as a monomer and as a complex. GSTM3 was present 
in all of the lysates as a monomer and also followed the exosome profile of GSTM1 
where it was present monomerically in only LNCaP and DU145 exosomes. This 
suggests that some GSTs and possibly other proteins are preferentially packaged 
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into exosomes. This packaging may be a way to remove unnecessary products from 
the cell or the exosomes themselves may be used as a means of transportation for 
particular enzymes to other cells. The presence of dimeric GSTM1 is interesting as 
the western blotting conditions (denaturing and reducing) should only yield 
monomeric protein. Exosome function has been linked to tumour progression as 
they act as mediators between the localised tumour and distant metastases [Quail, 
2013]. After being released, the proteins within these exosomes may affect tumour 
growth and this probably is the case for GSTM1. Unlike the other GSTs that were 
studied, GSTP1 was present in both the DU145 and PC3 lysates and exosomes and 
also only contained only monomeric GSTP1. The lysate profile was expected as the 
results correlated with a previous study [Hokaiwado, 2008]. 
GSTM1 was stably over-expressed in 22Rv1 cells and subsequently 
packaged into shed exosomes that were shown to serve a biological purpose in 
which the proliferation of prostate cancer cells and stromal prostatic fibroblasts 
increased as 22Rv1-M1 exosomes were added both in the presence or absence of 
docetaxel. The addition of exosomes themselves (22Rv1-VO) was shown to 
increase proliferation in DU145, PC3 and LNCaP at both exosome concentrations. 
The increased proliferation of DU145 cells both in the absence and presence of 
docetaxel was very similar. This was expected as DU145 cells are docetaxel 
resistant, so cell growth was not hindered with 20 nM docetaxel. The proliferation of 
22Rv1 cells when treated with 22Rv1-VO exosomes did not increase. This was also 
expected since the exosomes were originally derived from 22Rv1 cells and would 
contain the same proteins and miRNA. Proliferation increased significantly when 
200 µg/mL 22Rv1-M1 exosomes were added to 22Rv1 cells and this shows that 
loading GSTM1 into exosomes helps cell growth when culturing with and without 
docetaxel. When 22Rv1-VO and 22Rv1-M1 exosomes were added to the docetaxel 
sensitive cell lines PC3 and LNCaP, the proliferation of these tumour cells increased 
significantly. The LNCaP cells that were cultured with docetaxel showed particularly 
interesting results as tumour growth was increased with a very high concentration of 
docetaxel. The IC50 for LNCaP cells was 2 nM at 72 hours (Figure 4.2) however 
when vector and over-expressing exosomes were added to the culture, the 
proliferation increased significantly. This shows that exosomes themselves and 
GSTM1 over-expressing exosomes played a protective role in LNCaP cells from 
docetaxel. 
There are many possible future directions that have stemmed from this 
study. The over-expression of GSTM1 could be performed in other prostate cancer 
cell lines particularly LNCaP cells where it was already strongly expressed. GSTM3 
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could perhaps be over-expressed in 22Rv1 cells and the exosomes collected from 
this over-expressing cell line to see if there is also a functional effect as it has not 
yet been studied. These shed exosomes could be used in functional studies such as 
the same proliferation studies that were performed during this study. The effect of 
these exosomes on cell migration could also be tested using a transwell migration 
assay. This would include using a Boyden chamber to observe the migration of cells 
from the top layer to the bottom to see if the addition of exosomes increases or 
decreases the rate of migration [Lee, 2013]. The exosomes from DU145 and PC3 
cells that already express GSTP1 could also be used in proliferation and migration 
studies. As there was no GSTT1 in any shed exosomes, this lack of GSTT1 can be 
studied with these exosomes. GSTP1, GSTM1 and GSTM3could be over-expressed 
in normal prostate cells such as RWPE-1 or prostatic stromal cells like WPMY-1 and 
exosomes shed from these manipulated cells could then be used in similar 
functional studies to see if over-expression resulted in an increase or decrease in 
proliferation and if these transfected cells were less or more sensitive to 
chemotherapeutic drugs. 
Conversely, GST expression could also be silenced using short interfering 
RNA (siRNA). Lack of exosomal GSTs could be examined to see if unlike the over-
expression, silencing decreases docetaxel detoxification. Proliferation of these GST 
free cancer cells in the presence and absence of docetaxel can also be examined. 
The function of GSTs and exosomes can also be examined with using other 
chemotherapeutic drugs like doxorubicin and cisplatin alone or in conjunction with 
docetaxel [Tsakalozou, 2012]. These are also common drugs used in prostate 
cancer treatments that have different modes of action [McKay, 2015; Tsakalozou, 
2012].   
 Furthermore, experiments using clinical samples rather than cell lines could 
also be used to further enhance the study. Samples from healthy patients, to 
patients with BPH and patients with low or high Gleason score prostate cancer could 
be used. Exosomes would be isolated from seminal fluid, which is rich in 
prostasomes and exosomes, and the GST content examined. The process to isolate 
exosomes from clinical samples is outlined in Théry, 2006 and follows similar 
procedures as isolating exosomes from cell culture media. Following exosome 
characterisation, proliferation and migration studies could be performed both in the 
absence and presence of docetaxel or another chemotherapeutic drug, doxorubicin.    
The importance of exosomes in delivery of agents to inhibit tumour spread 
has previously been explored. A study by Kim et al. (2015) reported loading 
paclitaxel (PTX) within macrophage-released exosomes and the ability of these to 
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overcome multidrug resistance of cancer cells. In this study, the most effective 
method of loading PTX into exosomes was to sonicate the exosomes in the 
presence of PTX at 20% amplitude, 6 cycles for 30 seconds on/off for three minutes 
with a two minute cooling period between each cycle. After sonication, the exo-PTX 
solution was incubated at 37°C for 60 minutes to allow for the recovery of the 
exosomal membrane. By examining the levels of Alix, TSG101 and Flotillin in 
exosomes before and after sonication with Western blotting, it was apparent that 
sonication did not affect the protein content of the exosomes. There were also no 
major alterations of the lipid content of exosomal membranes. The final incubation 
hour resulted in a complete restoration of membrane microviscosity. The cup-
shaped morphology of exosomes also remained the same [Kim, 2015].  
A significant inhibition of lung metastasis growth by exo-PTX was seen in 
mice after IV injecting with exo-PTX compared to treatments with saline or Taxol 
[Kim, 2015]. Few cancer cells were seen in the lungs of exo-PTX treated animals 
and sonicated empty exosomes showed no significant inhibition on metastasis 
growth. When the intraluminal cargo is released into the cytosol of a target cells, any 
drug that is also in the inner bilayer of exosomes may also be used. Airway 
delivered exosomes showed almost complete co-localisation with cancer 
metastases [Kim, 2015]. It was speculated that macrophage-released exosomes 
were likely to have specific proteins on the surface allowing preferential 
accumulation in cancer cells [Kim, 2015]. The research described previously shows 
that an over-expressed protein, GSTM1, can be loaded into exosomes and this 
might be an approach that can be used to load anti-tumour molecules.  
Exosome-mediated cell to cell communication is important in the interactions 
of cancer cells with the immune system [Finn, 2012]. Parolini et al. (2009) showed 
that under acidic conditions, there was a more efficient fusion of exosomes with 
target cells suggesting that tumours in an acidic microenvironment may 
preferentially take up exosomes compared to the surrounding healthy tissue which 
may not be as acidic [Parolini, 2009]. Therapeutically, exosomes provide a good 
drug delivery system as they are able to be lyophilised and reconstituted and still 
retain their morphology and other characteristics meaning that exosomes containing 
drugs may be prepared and stored prior to treatment [Haney, 2015]. 
In summary, the progression of local PCa and any distant metastases 
includes the involvement of exosomes, particularly the macromolecules they 
contain. These macromolecules could have a positive or negative effect. This study 
shows that GST enzymes that are loaded as cargo in exosomes released from PCa 
cells may also effect the proliferation of these cells in vitro and be involved in cancer 
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progression in the presence and absence of chemotherapeutic drugs. This study 
provides a basis for further investigations into whether GSTs contained in exosomes 
can be used as useful biomarkers for diagnosis and prognosis of PCa or used as 
potential therapeutic targets. 
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Appendices 
 
Appendix A: Sequencing of GSTP1 in pGEM-T easy vector 
Sequencing of GSTP1 in the pGEM-T easy vector showed a base pair change at 
nucleotide +5 changing the corresponding amino acid from P to R (Proline to 
Arginine).  
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Appendix B: Sequencing of GSTP1 after site-directed mutagenesis 
Site-directed mutagenesis of the GSTP1 sequence showing the base change at 
nucleotide +5 from G to C. 
 
 
 
 
 
 
 
 
 
C C G 
